<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">58064</article-id><article-id pub-id-type="doi">10.7554/eLife.58064</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Methotrexate attenuates vascular inflammation through an adenosine-microRNA-dependent pathway</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-185757"><name><surname>Yang</surname><given-names>Dafeng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-185758"><name><surname>Haemmig</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-219613"><name><surname>Zhou</surname><given-names>Haoyang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219614"><name><surname>Pérez-Cremades</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-185759"><name><surname>Sun</surname><given-names>Xinghui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-185760"><name><surname>Chen</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-185761"><name><surname>Li</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-185762"><name><surname>Haneo-Mejia</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-185763"><name><surname>Yang</surname><given-names>Tianlun</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund16"/><xref ref-type="other" rid="fund17"/><xref ref-type="other" rid="fund18"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-185764"><name><surname>Hollan</surname><given-names>Ivana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-184145"><name><surname>Feinberg</surname><given-names>Mark W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9523-3859</contrib-id><email>mfeinberg@bwh.harvard.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Medicine, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University</institution><addr-line><named-content content-type="city">Changsha</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>Department of Pathology and Laboratory Medicine, Institute for Immunology, Perelman School of Medicine, University of Pennsylvania</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Division of Protective Immunity, Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Cardiology, Xiangya Hospital, Central South University</institution><addr-line><named-content content-type="city">Changsha</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution>Lillehammer Hospital for Rheumatic diseases</institution><addr-line><named-content content-type="city">Lillehammer</named-content></addr-line><country>Norway</country></aff><aff id="aff7"><label>7</label><institution>Norwegian University of Science and Technology</institution><addr-line><named-content content-type="city">Gjøvik</named-content></addr-line><country>Norway</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Tontonoz</surname><given-names>Peter</given-names></name><role>Reviewing Editor</role><aff><institution>University of California, Los Angeles</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Barton</surname><given-names>Matthias</given-names></name><role>Senior Editor</role><aff><institution>University of Zurich</institution><country>Switzerland</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>01</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e58064</elocation-id><history><date date-type="received" iso-8601-date="2020-04-20"><day>20</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-12-31"><day>31</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>© 2021, Yang et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Yang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-58064-v2.pdf"/><abstract><p>Endothelial cell (EC) activation is an early hallmark in the pathogenesis of chronic vascular diseases. MicroRNA-181b (<italic>Mir181b</italic>) is an important anti-inflammatory mediator in the vascular endothelium affecting endotoxemia, atherosclerosis, and insulin resistance. Herein, we identify that the drug methotrexate (MTX) and its downstream metabolite adenosine exert anti-inflammatory effects in the vascular endothelium by targeting and activating <italic>Mir181b</italic> expression. Both systemic and endothelial-specific <italic>Mir181a2b2</italic>-deficient mice develop vascular inflammation, white adipose tissue (WAT) inflammation, and insulin resistance in a diet-induced obesity model. Moreover, MTX attenuated diet-induced WAT inflammation, insulin resistance, and EC activation in a <italic>Mir181a2b2</italic>-dependent manner. Mechanistically, MTX attenuated cytokine-induced EC activation through a unique adenosine-adenosine receptor A3-SMAD3/4-<italic>Mir181b</italic> signaling cascade. These findings establish an essential role of endothelial <italic>Mir181b</italic> in controlling vascular inflammation and that restoring <italic>Mir181b</italic> in ECs by high-dose MTX or adenosine signaling may provide a potential therapeutic opportunity for anti-inflammatory therapy.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>endothelial cells</kwd><kwd>microRNA</kwd><kwd>inflammation</kwd><kwd>adenosine</kwd><kwd>methotrexate</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL115141</award-id><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL134849</award-id><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>18SFRN33900144</award-id><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>18POST34030395</award-id><principal-award-recipient><name><surname>Haemmig</surname><given-names>Stefan</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001610</institution-id><institution>Falk Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yang</surname><given-names>Tianlun</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL148207</award-id><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL148355</award-id><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL153356</award-id><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution>Arthur K Watson Charitable Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution>Dr. Ralph and Marian Falk Medical Research Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Swiss National Science Foundation</institution></institution-wrap></funding-source><award-id>P2BEP3_162063</award-id><principal-award-recipient><name><surname>Haemmig</surname><given-names>Stefan</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>18POST34030395</award-id><principal-award-recipient><name><surname>Haemmig</surname><given-names>Stefan</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>18SFRN33900144</award-id><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>20SFRN35200163</award-id><principal-award-recipient><name><surname>Feinberg</surname><given-names>Mark W</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>81570334</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Tianlun</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>81770358</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Tianlun</given-names></name></principal-award-recipient></award-group><award-group id="fund18"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100011790</institution-id><institution>Xiangya Hospital</institution></institution-wrap></funding-source><award-id>#013</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Tianlun</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Investigation into methotrexate's effects in the vascular endothelium reveals it exerts anti-inflammatory effects through a unique adenosine-adenosine receptor A3-SMAD3/4-miR-181b signaling axis with implications for controlling vascular inflammation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Activated endothelial cells (ECs) orchestrate the expression of adhesion molecules and release chemokines to foster the recruitment of leukocytes into the vessel wall. This presents an early hallmark that contributes to the development of chronic vascular disease states, such as atherosclerosis, insulin resistance, and rheumatoid arthritis (RA) (<xref ref-type="bibr" rid="bib24">Khan et al., 2010</xref>; <xref ref-type="bibr" rid="bib38">Rao et al., 2007</xref>; <xref ref-type="bibr" rid="bib42">Speyer and Ward, 2011</xref>; <xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). Accumulating studies demonstrate that targeting EC activation and/or dysfunction may open new therapeutic approaches for the prevention and treatment of inflammatory diseases (<xref ref-type="bibr" rid="bib7">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Gareus et al., 2008</xref>; <xref ref-type="bibr" rid="bib36">Nus et al., 2016</xref>). For example, inhibition of NF-κB activity specifically in the vascular endothelium significantly reduced atherosclerotic plaque formation and progression (<xref ref-type="bibr" rid="bib16">Gareus et al., 2008</xref>).</p><p>MicroRNAs (miRNAs), a class of evolutionary conserved small non-coding RNAs, are important post-transcriptional regulators of gene expression through mRNA degradation or translational repression (<xref ref-type="bibr" rid="bib29">Loyer et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Sun et al., 2013</xref>). We have previously identified microRNA-181b (<italic>Mir181b</italic>), an anti-inflammatory miRNA, which prevents EC activation and diverse vascular inflammatory disease states including endotoxemia, atherosclerosis, insulin resistance, and arterial thrombosis (<xref ref-type="bibr" rid="bib27">Lin et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>), suggesting that <italic>Mir181b</italic> could serve as a promising target for preventing EC activation and dysfunction associated with inflammatory diseases. <italic>Mir181b</italic> expression is significantly reduced in response to a range of pro-inflammatory stimuli in the vascular endothelium (<xref ref-type="bibr" rid="bib27">Lin et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). Therefore, identification of signaling pathways or therapeutics to rescue <italic>Mir181b</italic> expression in the vascular endothelium could open new strategies to control vascular inflammation.</p><p>Methotrexate (MTX) is a first-line treatment in RA and other autoimmune-mediated inflammatory diseases. Observational studies suggested that low-dose MTX could reduce cardiovascular risk in patients with RA (<xref ref-type="bibr" rid="bib5">Charles-Schoeman et al., 2017</xref>; <xref ref-type="bibr" rid="bib12">Deyab et al., 2017</xref>; <xref ref-type="bibr" rid="bib21">Hjeltnes et al., 2013</xref>; <xref ref-type="bibr" rid="bib25">Kisiel et al., 2015</xref>). For example, the Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid Arthritis Study (PSARA) demonstrated that patients receiving MTX improved endothelial function and reduced E-selectin plasma levels after 6 months follow-up (<xref ref-type="bibr" rid="bib12">Deyab et al., 2017</xref>; <xref ref-type="bibr" rid="bib21">Hjeltnes et al., 2013</xref>). Another clinical trial identified that MTX treatment significantly lowered carotid intima-media thickness in RA patients compared to placebo (<xref ref-type="bibr" rid="bib25">Kisiel et al., 2015</xref>). However, the recent Cardiovascular Inflammation Reduction Trial (CIRT), designed to determine the effect of low-dose MTX on cardiovascular secondary prevention, found that low-dose MTX did not reduce cardiovascular events compared to placebo (<xref ref-type="bibr" rid="bib40">Ridker et al., 2019</xref>). These conflicting results from different clinical trials raise questions for the mechanisms of MTX-mediated effects on vascular inflammation. While adenosine has been identified as a potential metabolite activated in response to MTX in ECs (<xref ref-type="bibr" rid="bib19">Haskó and Cronstein, 2013</xref>), gaps remain in our understanding of the downstream signaling pathways underlying its effects.</p><p>In this study, we identify that high-dose MTX and its downstream metabolite adenosine exert anti-inflammatory effects in the vascular endothelium through an MTX-adenosine receptor A3-<italic>Mir181b-</italic>dependent signaling pathway. These results provide a general paradigm for therapeutic control of miRNA expression and that restoring <italic>Mir181b</italic> expression in the vascular endothelium by high-dose MTX or adenosine signaling may provide therapeutic opportunities for anti-inflammatory therapy.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>MTX attenuates TNF-α-induced EC activation by upregulation of MIR181B-2 expression</title><p>Because of their known anti-inflammatory effects in the vascular endothelium (<xref ref-type="bibr" rid="bib13">Diamantis et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Mangoni et al., 2017</xref>), we explored whether MTX or HMG-CoA reductase inhibitors (statins) activated the expression of the anti-inflammatory <italic>MIR181B</italic> (<xref ref-type="bibr" rid="bib27">Lin et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). MTX (10 µM) but not statins significantly upregulated <italic>MIR181B</italic> expression by 1.35-fold in cultured human umbilical vein endothelial cells (HUVECs) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The MTX-induced expression of <italic>MIR181B</italic> was dose- and time-dependent with the highest induction at 10 µM and 4 hr (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>). Previous studies have established that adenosine (Ad) is the major anti-inflammatory effector of MTX, which is a product of adenosine monophosphate, a reaction catalyzed by the enzyme ecto-5’ nucleotidase (<xref ref-type="bibr" rid="bib4">Chan and Cronstein, 2013</xref>; <xref ref-type="bibr" rid="bib14">Gadangi et al., 1996</xref>; <xref ref-type="bibr" rid="bib50">Tian and Cronstein, 2007</xref>). When using a competitive enzyme inhibitor of ecto-5’ nucleotidase (α, β-methylene adenosine-5’-diphosphate (APCP)), the MTX-induced <italic>MIR181B</italic> expression was completely blocked (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Conversely, Ad alone increased <italic>MIR181B</italic> expression in a dose- and time-dependent manner with the highest observed increase by 2.3-fold at 50 µM and 4 hr (<xref ref-type="fig" rid="fig1">Figure 1E,F</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Methotrexate (MTX) represses TNF-α-induced pro-inflammatory gene expression via upregulation of <italic>MIR181B-2</italic> expression in ECs.</title><p>(<bold>A</bold>) Real-time qPCR analysis of mature <italic>MIR181B</italic> in HUVECs in the presence or absence of MTX (10 µM), Atorvastatin (1 µM), Mevastatin (1 µM), Simvastatin (1 µM), and Rosuvastatin (1 µM) for 4 hr. three biological replicates. Unpaired two-tailed Student <italic>t</italic> test. (<bold>B</bold>) Titration of MTX (0 to 100 µM) for 4 hr (three biological replicates, Unpaired two-tailed Student <italic>t</italic> test) and (<bold>C</bold>) time course of MTX (10 µM) in HUVECs to assess <italic>MIR181B</italic> expression, three biological replicates. One-way ANOVA. (<bold>D</bold>) Real-time qPCR analysis of <italic>MIR181B</italic> in HUVECs incubated with MTX (10 µM) or in combination with APCP (50 µM) for 4 hr. Three biological replicates. Unpaired two-tailed Student <italic>t</italic> test. (<bold>E</bold>) Dose-response of adenosine (Ad) (0 to 100 µM) for 4 hr and (<bold>F</bold>) time course of Ad (50 µM) over 0–12 hr on <italic>MIR181B</italic> expression in HUVECs. Three biological replicates. One-way ANOVA. (<bold>G</bold>) HUVECs were treated with TNF-α (10 ng/ml) alone or in combination with either MTX (10 µM) or Ad (50 µM) for 4 hr. Three biological replicates. Unpaired two-tailed Student <italic>t</italic> test. Analysis of primary transcript of (<bold>H</bold>) <italic>MIR181B-2</italic> (<italic>Pri-MIR181B-2</italic>) or (<bold>I</bold>) <italic>MIR181A-2</italic> (<italic>Pri-MIR181A-2</italic>) in response to TNF-α (10 ng/ml) with or without MTX (10 µM) or Ad (50 µM) for 4 hr in HUVECs. Three biological replicates. Unpaired two-tailed Student <italic>t</italic> test. (<bold>J</bold>) Isolated primary lung endothelial cells (ECs) from <italic>Mirr181a2b2</italic><sup>flox/flox</sup> (flox) mice and <italic>Mir181a2b2</italic><sup>-/-</sup> (KO) mice were treated with TNF-α (10 ng/ml) with or without MTX (10 µM) or Ad (50 µM) for 8 hr to analyze <italic>VCAM-1</italic> protein expression. Please see <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>. Three biological replicates. Unpaired two-tailed Student <italic>t</italic> test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001. n.s. indicated non significance. All values represent mean ± SEM.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58064-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Methotrexate (MTX) and Ad repress TNF-α-induced pro-inflammatory genes without affecting primary <italic>MIR181A-1</italic> and <italic>MIR181B-1</italic> expression.</title><p>(<bold>A</bold>) Western blot analysis of VCAM-1, ICAM-1, and E-Selectin in HUVECs treated with or without MTX (10 µM) or Ad (50 µM), after stimulation of TNF-α (10 ng/ml) for 8 hr. Quantification of n = 3 independent experiments. (<bold>B</bold>) Real-time qPCR analysis of VCAM-1, ICAM-1, and E-Selectin in HUVECs treated with or without MTX (10 µM) or Ad (50 µM), after treatment with TNF-α (10 ng/ml) for 4 hr. Real-time qPCR analysis of (<bold>C</bold>) primary transcript of <italic>MIR181A1</italic> or (<bold>D</bold>) primary transcript of <italic>MIR181B-1</italic> in HUVECs treated with or without MTX (10 µM) or Ad (50 µM), after treatment with TNF-α (10 ng/ml) for 4 hr. (<bold>A–D</bold>), n = 3–6. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ***p&lt;0.0001. All values represent mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig1-figsupp1-v2.tif"/></fig></fig-group><p><italic>MIR181B</italic> expression is rapidly reduced in response to pro-inflammatory stimuli such as TNF-α in ECs and overexpression <italic>MIR181B</italic> suppressed TNF-α-induced EC activation by repressing <italic>VCAM-1</italic>, <italic>E-selectin</italic>, and <italic>ICAM-1</italic> expression (<xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib54">Yamasaki et al., 2003</xref>). To address whether MTX or Ad may rescue the TNF-α-mediated reduction in <italic>MIR181B</italic> expression, HUVECs were stimulated with TNF-α in combination with either MTX or Ad. Treatment with MTX or Ad fully rescued the TNF-α repression of <italic>MIR181B</italic> expression (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). As expected, ECs treated with MTX or Ad significantly reduced <italic>VCAM-1</italic>, <italic>ICAM-1,</italic> and <italic>E-selectin</italic> expression stimulated by TNF-α (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>). Because two loci for <italic>MIR181B</italic> (i.e. <italic>MIR181B-1</italic> and <italic>MIR181B-2</italic>) exist (<xref ref-type="bibr" rid="bib45">Sun et al., 2014b</xref>), we examined which locus is regulated by TNF-α, MTX, or Ad. To this end, primary miRNA transcripts were analyzed in response to stimulation with TNF-α. Only primary transcript of the <italic>MIR181B-2</italic> locus, and not primary <italic>MIR181B-1</italic>, <italic>MiR-181A-1</italic>, or <italic>MiR-181A-2</italic>, was rescued by MTX or Ad co-stimulation (<xref ref-type="fig" rid="fig1">Figure 1H,I</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C,D</xref>).</p><p>To study the relationship between MTX or Ad to <italic>Mir181b</italic> in mouse tissues, primary lung ECs were isolated from <italic>Mir181a2b2</italic><sup>—/—</sup> knockout mice (KO), reflecting deficiency of <italic>Mir181a-2</italic> and <italic>Mir181b-2</italic>, or control <italic>Mir181a2b2</italic><sup>flox/flox</sup> (flox). Because <italic>Mir181a-2</italic> and <italic>Mir181b-2</italic> are located in close proximity to each other, the knockout strategy deleted both miRNAs (<xref ref-type="bibr" rid="bib20">Henao-Mejia et al., 2013</xref>). Isolated primary ECs were stimulated with TNF-α in the presence or absence of MTX or Ad. In ECs isolated from wild-type flox mice, MTX or Ad inhibited VCAM-1 protein expression by 40% and 35%, respectively. However, MTX or Ad did not reduce VCAM-1 expression in primary ECs from <italic>Mir181a2b2</italic><sup>—/—</sup> KO mice (<xref ref-type="fig" rid="fig1">Figure 1J</xref>). Taken together, these findings suggest that pri-<italic>Mir181b-2</italic> and its mature isoform <italic>Mir181b</italic> is increased by MTX or Ad, and may mediate the protective anti-inflammatory effects of MTX or Ad on TNF-α-induced EC activation.</p></sec><sec id="s2-2"><title>Adenosine receptor A3 (ADORA3) mediates MTX-induced expression of MIR181B in ECs</title><p>Ad is released by cells to the extracellular environment at a low concertation and acts as a local modulator with a generally cytoprotective function through interaction with its four cell surface Ad receptors, <italic>ADORA1</italic>, <italic>ADORA2A</italic>, <italic>ADORA2B,</italic> and <italic>ADORA3</italic>. Each of these Ad receptors have a unique pharmacological profile, tissue distribution, and effector coupling (<xref ref-type="bibr" rid="bib18">Haskó and Cronstein, 2004</xref>; <xref ref-type="bibr" rid="bib22">Jacobson and Gao, 2006</xref>). To examine which Ad receptor mediates the MTX-induced <italic>MIR181B</italic> expression, individual knockdown for each of the Ad receptors was performed in ECs first in the absence of MTX or Ad (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–H</xref>). Only silencing of <italic>ADORA3</italic> reduced <italic>MIR181B</italic> basal expression by 40%, while knockdown of <italic>ADORA1</italic>, <italic>ADORA2A, and ADORA2B</italic> had no effect on <italic>MIR181B</italic> expression (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). This suggests that <italic>ADORA3</italic> might mediate the <italic>MIR181B</italic> expression activated by MTX or Ad. Therefore, we next examined whether AdoRA<sub>3</sub> knockdown blocked the MTX or Ad-mediated increase in <italic>MIR181B</italic> expression. Indeed, neither MTX nor Ad increased <italic>MIR181B</italic> expression in <italic>ADORA3</italic>-deficient HUVECs compared to negative control siRNA (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). <italic>MIR181B</italic> expression is reduced in response to pro-inflammatory stimuli such as TNF-α (<xref ref-type="bibr" rid="bib27">Lin et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). Treatment of ECs with TNF-α in the presence of MTX or Ad rescued the TNF-α-mediated repression of <italic>MIR181B</italic> expression in an AdoRA<sub>3</sub>-specific manner (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Furthermore, silencing of <italic>ADORA3</italic>, (and not <italic>ADORA1</italic>, <italic>ADORA2A</italic>, or <italic>ADORA2B</italic>) abrogated the anti-inflammatory effect of MTX or Ad in TNF-α-activated ECs on <italic>VCAM-1</italic>, <italic>ICAM-1,</italic> and <italic>E-Selection</italic> expression (<xref ref-type="fig" rid="fig2">Figure 2D</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Finally, to further assess whether the anti-inflammatory effect of MTX or Ad is mediated through an <italic>ADORA3-MIR181B</italic> signaling cascade, knockdown of <italic>ADORA3</italic> was combined with simultaneous overexpression of <italic>MIR181B</italic> mimic. While the MTX or Ad anti-inflammatory effects were blocked in the presence of <italic>ADORA3</italic> silencing, overexpression of <italic>MIR181B</italic> fully rescued the MTX and Ad-mediated reduction of ECs activation markers (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). In summary, our data indicate that <italic>ADOR3</italic> plays central role in mediating MTX- or Ad-induced <italic>MIR181B</italic> expression, and this <italic>ADORA3-MIR181B</italic> signaling pathway contributes to the inhibitory effects of MTX or Ad on TNF-α-induced EC activation.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Induction of <italic>MIR181B</italic> expression by methotrexate (MTX) or adenosine is adenosine receptor A<sub>3</sub> (<italic>ADORA3</italic>) dependent.</title><p>(<bold>A</bold>) Knockdown for adenosine receptors A1, A2A, A2B, and A3 in HUVECs was performed to analyze <italic>MIR181B</italic> expression. three biological replicates. One-way ANOVA. (<bold>B</bold>) <italic>MIR181B</italic> expression in HUVECs transfected with Ctl-siRNA or <italic>ADORA3</italic> siRNA after treatment with MTX (10 µM) or Ad (50 µM) or (<bold>C</bold>) treatment with TNF-α (10 ng/ml) alone or in combination MTX (10 µM) or Ad (50 µM). Three biological replicates. One-way ANOVA and Unpaired two-tailed Student <italic>t</italic> test. (<bold>D</bold>) Western blot analyses of <italic>VCAM-1</italic>, <italic>ICAM-1</italic>, and <italic>E-Selectin</italic> expression in HUVECs transfected with Ctl-siRNA or <italic>ADORA3</italic> siRNA in the presence of TNF-α (10 ng/ml) in combination with either MTX (10 µM) or Ad (50 µM). Three biological replicates. Unpaired two-tailed Student <italic>t</italic> test. (<bold>E</bold>) in the presence of miRNA negative control (NS-m) or <italic>MIR181B</italic> mimics (181b-m) stimulated with TNF-α (10 ng/ml) or in combination with MTX (10 µM) or Ad (50 µM). Please see <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. Three biological replicates. Unpaired two-tailed Student <italic>t</italic> test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001. n.s. indicated non significance. All values represent mean ± SEM.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58064-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Knockdown efficiency for adenosine receptor siRNAs.</title><p>mRNA, and protein expression analysis for (<bold>A, B</bold>) <italic>ADORA3</italic> siRNA, (<bold>C, D</bold>) <italic>ADORA1</italic> siRNA, (<bold>E, F</bold>) <italic>ADORA2A</italic> siRNA and (<bold>G, H</bold>) <italic>ADORA2B</italic> siRNA compared to control siRNA in HUVECs transfected for 36 hr. (<bold>A–H</bold>), n = 3. ***p&lt;0.001. All values represent mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>MTX and Ad regulate MIR181B-2 promoter activity via SMAD3/4</title><p>To address, how MTX regulates <italic>MIR181B-2</italic> expression on the transcriptional level, different lengths of the proximal <italic>MIR181A2B2</italic> promoter (containing sequences 5’ to both MIR181A-2 and MIR181B-2) were cloned upstream of a luciferase reporter. MTX and Ad activated the −606 bp <italic>MIR181A2B2</italic> promoter reporter construct from 1.47- to 1.57-fold, respectively (<xref ref-type="fig" rid="fig3">Figure 3A–B</xref>). Treatment of MTX or Ad similarly activated the −402 bp reporter comparable to the full-length constructs (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). However, reducing the promoter length to −301 bp or −150 bp significantly reduced luciferase activity from 30- to 2600-fold, respectively (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). At the post-transcriptional level, mRNA stability is an important factor determining mRNA abundance. To investigate whether MTX or Ad would affect pri-<italic>MIR181B-1</italic> or pri- <italic>MIR181B-2</italic> transcript stability, we used the transcription inhibitor actinomycin D in MTX or Ad-treated HUVECs. We found that neither MTX nor Ad affected the stability of pri-<italic>MIR181B-1</italic> transcript (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). However, MTX significantly increased pri-<italic>MIR181B-2</italic> transcript stability, while Ad had a modest opposite effect (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>). These results indicate that the promoter region between −402 and −301 is likely required for MTX and Ad-induced transcriptional activity of the <italic>MIR181A2B2</italic> locus and MTX and Ad affects pri-<italic>MIR181B-2</italic> expression at both transcriptional and post-transcriptional levels. To further identify specific transcription factor binding sites, in silico prediction tools identified a SMAD2/3/4 binding site in the region −402 to −301 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). This was further investigated by individual knockdown of <italic>SMAD2, SMAD3</italic>, or <italic>SMAD4</italic> (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). Silencing of <italic>SMAD3</italic> or <italic>SMAD4</italic> reduced luciferase activity of the full length −606 bp construct by 37% and 42%, respectively, in ECs compared to control siRNA (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). However, <italic>SMAD2</italic> silencing did not impact luciferase activity (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Consistent with this observation, <italic>MIR181B</italic> expression was significantly reduced only by silencing <italic>SMAD3</italic> or <italic>SMAD4</italic>, and not by <italic>SMAD2</italic> knockdown (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Importantly, silencing of <italic>SMAD3</italic> or <italic>SMAD4</italic> completely blocked the MTX and Ad-mediated increase in <italic>MIR181B</italic> expression (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Furthermore, knockdown <italic>ADORA3</italic> blocked the <italic>MIR181A2B2</italic> promoter luciferase activity induced by MTX and Ad (<xref ref-type="fig" rid="fig3">Figure 3F</xref>); however, silencing of the other three Ad receptors had no effect on luciferase activity (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). Taken together, these data indicate that <italic>SMAD3</italic> and <italic>SMAD4</italic> are not only required for transcriptional activity of <italic>MIR181B</italic> expression, but also significantly contribute to MTX and Ad-induced <italic>MIR181B</italic> expression.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>MIR181A2B2</italic> promoter analysis in response to methotrexate (MTX) or Ad in endothelial cells (ECs).</title><p>(<bold>A</bold>) Luciferase reporter constructs containing the indicated (0.606–5.1 kb 5’upstream) <italic>MIR181A2B2</italic> promoter sequences were transfected in HEK 293 T cells and luciferase activity was measured 12 hr after treatment with MTX (10 µM) or Ad (50 µM), respectively. eight biological replicates. One-way ANOVA. (<bold>B</bold>) Luciferase reporter constructs containing the indicated (0.606 kb 5’upstream) <italic>MIR181A2B2</italic> promoter sequences were transfected in HEK 293 T cells and luciferase activity was measured 12 hr after treatment with MTX (10 µM) or Ad (50 µM), respectively. Seven to eight biological replicates. One-way ANOVA. (<bold>C</bold>) Effect of siRNA-mediated knockdown for <italic>SMAD2</italic>, <italic>SMAD3</italic>, <italic>or SMAD4</italic> in response to MTX or Ad on the 0.606 kb luciferase reporter. Three biological replicates. Unpaired two-tailed Student <italic>t</italic> test. (<bold>D–E</bold>) Real-time qPCR analysis of <italic>MIR181B</italic> expression in HUVECs transfected with siRNAs to negative control, <italic>SMAD2</italic>, <italic>SMAD3</italic>, <italic>or SMAD4</italic> in the (<bold>D</bold>) absence or (<bold>E</bold>) presence of MTX (10 µM) or Ad (50 µM) for 4 hr. three biological replicates. Unpaired two-tailed Student <italic>t</italic> test. (<bold>F–G</bold>) Luciferase reporters containing the 0.606 kb miR-181a2b2 promoter were transfected in combination with siRNA to negative control or <italic>ADORA3</italic> (<bold>F</bold>) or <italic>ADORA1</italic>, <italic>ADORA2A</italic>, or <italic>ADORA2B</italic> (<bold>G</bold>) and stimulated with MTX (10 µM) or Ad (50 µM). Please see <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. four biological replicates. Unpaired two-tailed Student <italic>t</italic> test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001. All values represent mean ± SEM.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58064-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Silencing of adenosine receptor A1, A2A, or A2B did not affect methotrexate (MTX) or adenosine-induced <italic>MIR181B</italic> expression.</title><p>(<bold>A</bold>) Expression analysis of <italic>MIR181B</italic> in HUVECs transfected with siRNA to scrambled control, <italic>ADORA1</italic>, <italic>ADORA2A</italic>, or <italic>ADORA2B</italic> in the presence or absence of MTX (10 µM) or Ad (50 µM) for 4 hr. (<bold>B</bold>) VCAM-1 protein quantification by western blot as described above, but in the presence of TNF-α (10 ng/ml) for 8 hr. <bold>A</bold> and <bold>B</bold>, n = 3. *p&lt;0.05; **p&lt;0.01. All values represent mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>The effect of methotrexate (MTX) and Ad on pri-<italic>MIR181B-1</italic> and pri-<italic>MIR181B-2</italic> transcript stability.</title><p>HUVECs were incubated with 10 µg/ml Actinomycin D to inhibit transcription and treated with 10 µM MTX or 50 µM Ad. (<bold>A</bold>) Real-time qPCR analysis of pri- <italic>MIR181B-1</italic> transcript expression at indicated time points. (<bold>B</bold>) Real-time qPCR analysis of pri- <italic>MIR181B-2</italic> transcript expression at indicated time points. (<bold>A</bold>) and <bold>B</bold>), n = 3. *p&lt;0.05, **p&lt;0.01. All values represent mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>The knockdown efficiency for <italic>SMAD</italic> siRNA.</title><p>(<bold>A</bold>) Knockdown efficiency for (<bold>A</bold>) <italic>SMAD2</italic> siRNA, (<bold>B</bold>) <italic>SMAD3</italic> siRNA, and (<bold>C</bold>) <italic>SMAD4</italic> siRNA compared to siRNA control transfected HUVECs as quantified by real-time qPCR. (<bold>A–C</bold>), n = 3. ****p&lt;0.0001. All values represent mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig3-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>MTX improves insulin sensitivity and epididymal white adipose tissue (eWAT) inflammation in diet-induced obese mice, but not in Mir181a2b2<sup>-/-</sup> mice</title><p>Previous reports suggested that MTX can ameliorate diet-induced insulin resistance and inflammation (<xref ref-type="bibr" rid="bib11">DeOliveira et al., 2012</xref>; <xref ref-type="bibr" rid="bib35">Myers et al., 2017</xref>), although the mechanisms remained poorly understood. To evaluate the effective dose of MTX on <italic>Mir181b</italic> expression in vivo, C57Bl6 mice were injected with 0.5 mg/kg or 1.0 mg/kg of MTX. Low-dose (i.e. 0.25 mg/kg) MTX showed no significant increase in <italic>Mir181b</italic> expression in plasma, liver, and intima, but 1 mg/kg did (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Moreover, C57Bl6 mice treated with adenosine exhibited significantly elevated <italic>Mir181b</italic> expression in plasma by 168% and was even more pronounced than high-dose MTX (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). In accordance with this dose-response of MTX on <italic>Mir181b</italic> expression, we examined whether the effect of MTX (1 mg/kg) on insulin resistance and adipose tissue inflammation is dependent on <italic>Mir181b2</italic> expression in vivo. To this end <italic>Mir181a2b2</italic><sup>flox/flox</sup> (flox) and <italic>Mir181a2b2</italic><sup>—/—</sup> (KO) mice were placed on a 60% high-fat diet (HFD) for 12 weeks. Both flox and KO mice were injected with vehicle or MTX for 12 weeks (1 mg/kg/week by intraperitoneal injection), and insulin tolerance testing (ITT) and glucose tolerance testing (GTT) were performed (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). As shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref>, the body weights among the four groups were not significantly different, which suggest that the gain of body weight was independent of <italic>Mir181a2b2</italic> expression and MTX treatment. However, MTX treatment significantly improved insulin sensitivity and reduced the area under curves (AUC) for ITT by 23% (<xref ref-type="fig" rid="fig4">Figure 4C</xref>) compared with vehicle injected flox mice, but not in glucose tolerance (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). In line with our previous report showing a protective effect of <italic>Mir181b</italic> mimics on insulin resistance (<xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>), KO mice developed insulin resistance (IR) as shown by improved insulin sensitivity (increased AUC for ITT by 121%) and glucose tolerance (increased AUC GTT by 122%) (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>). Notably, the beneficial effect of MTX on insulin sensitivity was completely blocked in KO mice (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>). Moreover, flox mice treated with MTX had increased insulin signaling activity in eWAT and liver compared vehicle injected, indicated by an increase in phosphorylation of Akt (phospho-Akt) in eWAT (by 23%) and in liver (by 34%) (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). In contrast, KO mice without MTX injections showed a significant reduction of Akt phosphorylation by 24% in eWAT and 44% in liver compared with control flox mice (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Moreover, the MTX-mediated upregulation of phospho-Akt in eWAT and liver was blocked in KO mice (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). However, MTX did not increase phospho-Akt levels in skeletal muscle (SM) (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Taken together, these findings from systemic miR-181a2b2 KO mice suggest that MTX increases Akt phosphorylation in eWAT and liver through miR-181a2b2 expression, which contributes to improved insulin sensitivity.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Systemic <italic>Mir181a2b2</italic> KO blocks methotrexate (MTX)-mediated insulin sensitivity and visceral fat inflammation in diet-induced obesity.</title><p>(<bold>A</bold>) Schema of experimental procedure for <italic>Mir181a2b2</italic> <sup>flox/flox</sup> (flox) and <italic>Mir181a2b2</italic><sup>—/—</sup> (KO) mice that were placed on a 60% high-fat diet (HFD) for 12 weeks. Each group of mice was weekly i.p. injected with vehicle control or MTX (1 mg/kg). (<bold>B</bold>) Body weights were measured weekly. Blood glucose levels were measured at week 11 for (<bold>C</bold>) insulin tolerance testing (ITT) and on week 12 for (<bold>D</bold>) glucose tolerance testing (GTT) with calculated area under the curves (AUC), respectively. (<bold>E</bold>) Western blot analysis of Akt and pSer473-Akt in epididymal white adipose tissue (eWAT), liver, and skeletal muscle with quantification across n = 3 independent experiments. (<bold>F</bold>) Real-time qPCR analysis of VCAM-1 expression in eWAT. (<bold>B–F</bold>), n = 9–10 mice per group, one-way ANOVA. (<bold>G</bold>) Paraffin sections of eWAT were stained with Mac2 and the positive areas were quantified, n = 5 mice per group, one-way ANOVA. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001. All values represent mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>MTX and Ad increase <italic>Mir181b</italic> expression in the circulation and tissues.</title><p>(<bold>A</bold>) Real-time qPCR analysis of <italic>Mir181b</italic> expression in plasma, liver, intimal ECs, and aortic media from C57BL/6J mice that were tail vein injected with vehicle or MTX (0.25 mg/kg or 1 mg/kg) or (<bold>B</bold>) MTX or Ad for 3 hr. (<bold>A–B</bold>), n = 3 mice per group. *p&lt;0.05, **p&lt;0.01. All values represent mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Gene set enrichment analyses of eWAT from <italic>MiR181a2b2</italic> flex and KO mice.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig4-figsupp2-v2.tif"/></fig></fig-group><p>To better characterize the underlying mechanisms how MTX and <italic>Mir181a2b2</italic> affects insulin resistance, we performed next-generation sequencing of RNA isolated from eWAT of these HFD-fed <italic>Mir181a2b2</italic> flox and KO mice with or without MTX treatment. Gene set enrichment analysis (GSEA) suggested that the most statistically significant [false discovery rate (FDR) &lt; 0.5] altered genes in eWAT from <italic>Mir181a2b2</italic> KO mice were linked to cell adhesion (e.g. platelet-endothelium-leukocyte interactions, cell-matrix interactions, and cell junctions), chemotaxis, and immune response (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A-B</xref>). In eWAT from MTX-treated <italic>Mir181a2b2</italic> flox and KO mice, GSEA found that cell cycle, inflammation, and chemotaxis pathways were more affected by MTX (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C-D</xref>). Macrophage accumulation plays a critical role in obesity-associated IR (<xref ref-type="bibr" rid="bib6">Chawla et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">McNelis and Olefsky, 2014</xref>) and overexpression of <italic>Mir181b</italic> did not directly regulate cell-intrinsic monocyte/macrophage migration, proliferation, and activation (<xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). Moreover, we confirmed that MTX administration reduced <italic>VCAM-1</italic> mRNA expression by 36% in eWAT in flox mice, but not MTX-injected KO mice (<xref ref-type="fig" rid="fig4">Figure 4F,G</xref>). In line with reduced <italic>VCAM-1</italic> expression, we observed that macrophage content, as indicated by Mac2 staining, was significantly reduced by 80% in eWAT in MTX-injected flox mice (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). In contrast, KO mice treated with MTX showed no inhibitory effect on <italic>VCAM-1</italic> mRNA expression and macrophage content in eWAT (<xref ref-type="fig" rid="fig4">Figure 4F,G</xref>). Taken together, these results suggest that MTX administration leads to reduced EC activation and macrophage accumulation in white adipose tissue, largely dependent on <italic>Mir181a2b2</italic> expression.</p></sec><sec id="s2-5"><title>MTX improves insulin sensitivity in obese mice, but not in EC-specific Mir181a2b2 KO mice</title><p>It is well-established that some miRNAs may have a cell-type and/or tissue-specific expression and function which can impact the regulation of gene networks (<xref ref-type="bibr" rid="bib15">Gao et al., 2011</xref>; <xref ref-type="bibr" rid="bib41">Sood et al., 2006</xref>; <xref ref-type="bibr" rid="bib47">Thomou et al., 2017</xref>; <xref ref-type="bibr" rid="bib56">Zhou et al., 2013</xref>). <italic>Mir181b</italic> plays a dominant role in the vascular endothelium (<xref ref-type="bibr" rid="bib27">Lin et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>); however, its EC-specific genetic deletion has not been previously described. To assess whether endothelial <italic>Mir181a2b2</italic> is mediating the observed phenotypes with respect to MTX and insulin sensitivity, we generated inducible EC-specific <italic>Mir181a2b2</italic> mice (iEC-KO) by breeding the <italic>Mir181a2b2</italic><sup>flox/flox</sup> mice to tamoxifen-inducible endothelial-specific Cre (vascular endothelial cadherin promoter [VECad-Cre-ER<sup>T2</sup>]) (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Compared to vehicle control injected mice, <italic>Mir181b</italic> expression in tamoxifen injected iEC-KO mice was reduced by 60% and 80% in aortic intima and ECs isolated from SM, respectively, but not in the aortic media and non-EC fraction of SM (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B–E</xref>). To assess whether endothelial <italic>Mir181a2b2</italic> is driving the diet-induced IR and mediates MTX’s protective effects, we first examined MTX regulation of <italic>Mir181b</italic> expression. While <italic>Mir181b</italic> was reduced in the aortic intima of iEC-KO mice compared to flox-Cre, MTX increased <italic>Mir181b</italic> in flox-Cre, but not in iEC-KO mice (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>). Consistent with upregulated <italic>Mir181b</italic> expression, MTX reduced <italic>VCAM-1</italic> expression in the intima of flox-Cre mice, but not in iEC-KO mice (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>). Because we identified that SMAD3/4 signaling contributed largely to <italic>Mir181b2</italic> expression (<xref ref-type="fig" rid="fig3">Figure 3</xref>), we next investigated expression of SMADs in eWAT tissues from these HFD-fed flox-Cre and iEC-KO mice. We found that <italic>SMAD2</italic> and <italic>SMAD3</italic> expression decreased in MTX-treated iEC-KO mice compared to flox-Cre mice, whereas there were no differences between flox-Cre and iEC-KO mice without MTX treatment, suggesting a feedback mechanism involved in the MTX-SMAD-Mir181b cascade (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Endothelial cell (EC)-specific <italic>Mir181a2b2</italic> KO blocks methotrexate (MTX)-mediated insulin sensitivity and visceral fat inflammation in diet-induced obesity.</title><p>(<bold>A</bold>) Schema of experimental procedure for control <italic>Mir181a2b2</italic><sup>flox/flox</sup>; VECad-Cre (flox-Cre) or tamoxifen injected EC-specific <italic>Mir181a2b2</italic> KO (iEC-KO) mice that were placed on a 60% high-fat diet (HFD) for 15 weeks. Each group of mice was weekly i.p. injected with vehicle control or MTX (1 mg/kg). (<bold>B</bold>) Body weights over time of mice treated with vehicle or MTX, respectively. (<bold>C–D</bold>) ITT (<bold>C</bold>) and GTT (<bold>D</bold>) were measured and AUCs were quantified for each group. (<bold>E</bold>) Western blot analysis of Akt and pSer473-Akt in eWAT, liver, and skeletal muscle tissues. (<bold>F</bold>) Real-time qPCR analysis of VCAM-1 expression in eWAT. (<bold>G</bold>) Paraffin sections of eWAT were stained with Mac2 and the positive areas were quantified, n = 5 mice per group, one-way ANOVA. (<bold>B–G</bold>), n = 6 to 10 mice per group, one-way ANOVA. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001. All values represent mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Transcriptomic changes in eWAT of systemic <italic>Mir181a2b2</italic> KO mice in response to high-fat diet (HFD) and methotrexate (MTX).</title><p>(<bold>A</bold>) Gene set enrichment analysis after RNA-seq from eWAT of <italic>Mir181a2b2</italic><sup>—/—</sup> (KO) compared to <italic>Mir181a2b2<sup>f</sup></italic><sup>lox/flox</sup> (flox) mice placed on HFD diet for 12 weeks. (<bold>B</bold>) Gene network visualization of the top pathway for ‘Cell adhesion_Platelet-endothelium-leukocyte interactions’. (<bold>C</bold>) Gene set enrichment analysis after RNA-seq from eWAT of <italic>Mir181a2b2</italic><sup>—/—</sup> (KO) compared to <italic>Mir181a2b2</italic><sup>flox/flox</sup> (flox) mice placed on HFD and treatment with MTX for 12 weeks. (<bold>D</bold>) Gene network visualization of the top pathways for ‘Cell cycle’.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Breeding schema for creating endothelial-specific <italic>Mir181a2b2</italic> KO mouse strain.</title><p>(<bold>A</bold>) Real-time qPCR analysis of <italic>Mir181b</italic> expression in different tissues from <italic>Mir181a2b2</italic><sup>flox/flox</sup> and <italic>Mir181a2b2</italic><sup>—/—</sup> mice. (<bold>B</bold>) Schema showing strategy to generate endothelial <italic>Mir181a2b2</italic> knockout mice using tamoxifen (4-hydroxytamoxifen (4-OHT)). (<bold>C</bold>) Four-week-old male <italic>Mir181a2b2</italic><sup>flox/flox</sup>; VECad-Cre-ER<sup>T2</sup> mice were injected i.p. with corn oil vehicle control or 4-hydroxytamoxifen (4-OHT, 10 mg/kg) for 5 consecutive days before tissue expression of <italic>Mir181b</italic> was assessed at day 14. (<bold>D–E</bold>) <italic>Mir181b</italic> expression in intima and aortic media/adventitia (<bold>D</bold>) or in skeletal muscle (SM) ECs and non-ECs (NECs) isolated by CD31 beads (<bold>E</bold>). (<bold>A</bold>), n = 1. <bold>D</bold> and <bold>E</bold>, n = 3. *p&lt;0.05, ***p&lt;0.001. All values represent mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Western blot analysis of SMADs expression in eWAT from high-fat diet (HFD)-fed flox-Cre and iEC-KO mice treated with or without methotrexate (MTX) for 12 weeks.</title><p>(<bold>A</bold>) Western blot analysis of <italic>Smad2</italic>, <italic>Smad3</italic>, and <italic>Smad4</italic> expression in eWAT tissues from HFD-fed control flox-Cre and iEC-KO mice for 12 weeks. (<bold>B</bold>) Western blot analysis of <italic>Smad2</italic>, <italic>Smad3</italic>, and <italic>Smad4</italic> expression in eWAT tissues from HFD-fed control flox-Cre and iEC-KO mice treated with MTX for 12 weeks. (<bold>A</bold> and <bold>B</bold>), n = 4 mice per group. **p&lt;0.01. All values represent mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58064-fig5-figsupp3-v2.tif"/></fig></fig-group><p>As shown in <xref ref-type="fig" rid="fig5">Figure 5B</xref>, there were no significant differences in body weights between iEC-KO and control mice treated with or without MTX after 12 weeks of HFD. However, MTX administration significantly improved insulin sensitivity by 23% in ITT of control flox-Cre mice (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), whereas MTX had no effect on insulin sensitivity in iEC-KO mice (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Similar to <italic>Mir181a2b2</italic> systemic KO and control mice, MTX administration did not improve glucose tolerance either in iEC-KO or control mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Moreover, the MTX-mediated induction of Akt phosphorylation in eWATs and livers was blocked in iEC-KO mice (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Furthermore, MTX reduced <italic>VCAM-1</italic> expression in eWAT in flox-Cre control mice, but not in iEC-KO mice (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Consistent with previous results (<xref ref-type="fig" rid="fig4">Figure 4H</xref>), MTX administration significantly reduced Mac2 positive macrophage content in eWAT tissues in flox-Cre mice, whereas no effect was observed in iEC-KO mice (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Finally, iEC-KO mice without MTX treatment showed a significant increase in Mac2 positive macrophages compared to flox-Cre control mice in eWAT tissues (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Taken together, these results identify a crucial role of endothelial <italic>Mir181a2b2</italic> for mediating MTX’s anti-inflammatory effects.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Low-grade inflammation in adipose tissue plays a critical role in the pathogenesis of obesity-associated insulin resistance, an important risk factor for the development of cardiovascular disease and type 2 diabetes (<xref ref-type="bibr" rid="bib1">Arner and Kulyté, 2015</xref>). The Canakinumab Atherosclerosis Outcome Thrombosis Study (CANTOS) demonstrated that targeting inflammation reduces cardiovascular events by targeting interleukin-1β, independent of lipid lowering (<xref ref-type="bibr" rid="bib39">Ridker et al., 2017</xref>). In contrast, MTX, an anti-inflammatory drug that is widely used to treat patients with RA and psoriatic arthritis, did not reduce inflammatory markers, such as interleukin-1, interleukin-6, C-reactive protein, or cardiovascular events in the CIRT trail (<xref ref-type="bibr" rid="bib40">Ridker et al., 2019</xref>). The molecular mechanisms of how MTX reduces inflammation remains poorly understood. Previous studies found that Ad was the major downstream anti-inflammatory effector of MTX. By decreasing the catabolism of adenosine, MTX increases extracellular Ad, which in turn mediates its cellular effects via engagement of specific receptors (A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub>; <xref ref-type="bibr" rid="bib10">Cronstein and Sitkovsky, 2017</xref>). Among these adenosine receptors, A<sub>2A</sub> and A<sub>3</sub> are the most important receptors for mediating adenosine’s cellular anti-inflammatory effect (<xref ref-type="bibr" rid="bib8">Cronstein et al., 1993</xref>; <xref ref-type="bibr" rid="bib34">Montesinos et al., 2003</xref>).</p><p>MiRNAs are key post-transcriptional gene regulators and even moderate changes in miRNA expression can have profound functional impact in the vascular endothelium in response to divergent acute and chronic inflammatory conditions. For instance, we and others found that <italic>Mir181b</italic> expression was reduced by 40–60% in the vascular endothelium under atherosclerosis, sepsis, thrombosis, insulin resistance, and other conditions (<xref ref-type="bibr" rid="bib17">Guo et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Lin et al., 2016</xref>; <xref ref-type="bibr" rid="bib30">Ma et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). Overexpression of <italic>Mir181b</italic> by tail vein injection of <italic>Mir181b</italic> mimics (~1.5- to 2.5-fold increase in Mir181b expression) improved acute vascular inflammation induced by endotoxemia (<xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>), and chronic vascular inflammation triggered by atherosclerotic plaque formation (<xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>), obesity and insulin resistance (<xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>), and thrombin-induced arterial thrombosis (<xref ref-type="bibr" rid="bib27">Lin et al., 2016</xref>). In ECs, <italic>Mir181b</italic> inhibits NF-κB signaling by targeting importin-α3 or caspase recruitment domain family member 10 (Card10), whereas it activates phospho-Akt by targeting, pleckstrin homology domain leucine-rich repeat protein phosphatase isozyme2 (PHLPP2) (<xref ref-type="bibr" rid="bib27">Lin et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). Moreover, using an E-selectin-targeting microparticles system to deliver <italic>Mir181b</italic> specifically to the activated vascular endothelium, <italic>Mir181b</italic> significantly reduced atherosclerosis (<xref ref-type="bibr" rid="bib30">Ma et al., 2016</xref>). However, little is known how this anti-inflammatory Mir181b is regulated in ECs. While acute or chronic pro-inflammatory stimuli reduced <italic>Mir181b</italic> expression (<xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>), factors or signaling pathways that increase its expression in the vascular endothelium have not been defined.</p><p>Ad is continuously released by cells to the extracellular environment at a low concentration (less than 1 µM) in unstressed tissues, whereas Ad concentrations can reach as high as 100 µM in inflamed or ischemic tissues (<xref ref-type="bibr" rid="bib18">Haskó and Cronstein, 2004</xref>; <xref ref-type="bibr" rid="bib22">Jacobson and Gao, 2006</xref>). In addition, ECs are a major source of extracellular Ad at sites of metabolic distress, inflammation, and infection (<xref ref-type="bibr" rid="bib9">Cronstein, 1994</xref>). In agreement with a recently published report (<xref ref-type="bibr" rid="bib53">Xu et al., 2017</xref>), we found that Ad potently repressed TNF-α-induced inflammatory genes expression in an <italic>ADORA3</italic>-dependent manner, but not the other three Ad receptors. Moreover, we demonstrated that the MTX and Ad-mediated protective effects on ECs were dependent on Mir181b expression. Interestingly, silencing <italic>ADORA3</italic> decreased Mir181b expression, and blocked the TNF-α-mediated repression of Mir181b expression and abrogated the MTX- and Ad-mediated induction of <italic>Mir181b</italic> expression. Indeed, after TNF-α stimulation, the expression of adenosine kinase (ADK), a major intracellular adenosine metabolic enzyme, is increased and thereby results in decreased intracellular adenosine concentration, which in turn reduces extracellular adenosine (<xref ref-type="bibr" rid="bib53">Xu et al., 2017</xref>). Taken together, these data suggest that the MTX- and Ad-mediated induction of <italic>Mir181b</italic> expression is largely dependent on <italic>ADORA3</italic> expression. Moreover, the TNF-α-repression of <italic>Mir181b</italic> expression may be through a similar integrated network by inhibiting adenosine production and release and, in turn, <italic>ADORA3</italic> signaling.</p><p>Systemic <italic>MiR181a2b2</italic> KO and endothelial-specific-deficient <italic>Mir181a2b2</italic> mice exhibited EC activation, vascular inflammation, and insulin resistance in obese mice, suggesting that endothelial <italic>Mir181a2b2</italic> plays a key role in EC activation and progression of insulin resistance. Moreover, the anti-inflammatory effects and improvement in insulin sensitivity by MTX were dependent on endothelial <italic>Mir181a2b2</italic>. Mechanistically, MTX activated an Ad-<italic>ADORA3-SMAD3</italic>/4 signaling cascade that transcriptionally activated <italic>MIR181A2B2</italic> expression and modestly increased pri-<italic>MIR181B2</italic> mRNA stability at the post-transcriptional level. In light of these findings, the current study indicates that endothelial <italic>Mir181a2b2</italic> plays a critical role in diet-induced insulin resistance and mediates in part MTX’s anti-inflammatory effects. Moreover, our data suggest that high-dose of MTX (1 mg/kg) is essential to increase <italic>Mir181b</italic> expression and modulate a large gene network involving EC-leukocyte adhesion, chemotaxis, immune response, and cell cycle (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) in eWAT; consequently, this may ameliorate EC activation, insulin resistance, and adipose tissue inflammation. Several of these identified pathways (EC-leukocyte adhesion, chemotaxis, and immune response) are consistent with pathways known to be regulated by Mir181b (<xref ref-type="bibr" rid="bib17">Guo et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Lin et al., 2016</xref>; <xref ref-type="bibr" rid="bib30">Ma et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). In addition, <italic>Mir181a2b2</italic> KO mice exhibited more glucose intolerance under basal conditions compared to flox mice, and this response was further exacerbated by MTX treatment (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). While the mechanisms underlying this exaggerated response in the KO mice is not clear, we cannot rule out a participatory role of a broad range of tissues including the pancreas (<xref ref-type="bibr" rid="bib2">Baghdadi, 2020</xref>). In our prior study of HFD-induced obese mice, systemic delivery of <italic>Mir181b</italic> mimics (to overexpress <italic>Mir181b</italic>) improved insulin resistance and increased phospho-AKT in eWAT but not in liver or skeletal muscle (<xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). In this current study, MTX treatment potently increased phospho-Akt in liver, eWAT, and skeletal muscle in control mice (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), but not in those tissues from <italic>Mir181a2b2</italic><sup>—/—</sup> mice or in liver or eWAT in iECKO mice (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), suggesting that deficiency of miR-181a2b2 may figure more prominently in these tissues and underlie differences for phospho-AKT expression.</p><p>Previous studies demonstrated that MTX at a dose of 1–4 mg/kg more potently reduced inflammation (<xref ref-type="bibr" rid="bib11">DeOliveira et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Thornton et al., 2016</xref>). For example, the MUSICA trial demonstrated that high-dose MTX reduced inflammation (including circulating hsCRP) and RA disease activity better than low-dose MTX (<xref ref-type="bibr" rid="bib23">Kaeley et al., 2018</xref>). Our findings may also inform the lack of efficacy and anti-inflammatory effects of low-dose MTX in the CIRT study. Given the side effect profile of MTX including higher rates of mouth sores or stomatitis, liver enzyme elevations, mild leukopenia, and non-basal-cell skin cancers (<xref ref-type="bibr" rid="bib40">Ridker et al., 2019</xref>), future studies that therapeutically target signaling downstream to MTX (e.g. the adenosine-ADORA3-SMAD3/4-<italic>MIR181B</italic> signaling pathway) may leverage its anti-inflammatory effects potentially without its dose-limiting toxicity or side effects.</p><p>There are several limitations to our study. We cannot definitively bifurcate the contribution of <italic>Mir181b1</italic> or <italic>Mir181b2</italic> to EC activation and vascular inflammation. Mir181b is expressed from two distinct loci, that is the <italic>Mir181a-1</italic>/<italic>Mir181b-1</italic> cluster and the <italic>Mir181a-2</italic>/<italic>Mir181b-2</italic> cluster (<xref ref-type="bibr" rid="bib45">Sun et al., 2014b</xref>). In addition, <italic>Mir181a-1</italic>, <italic>Mir181a-2</italic>, <italic>Mir181b-1</italic>, <italic>and Mir181b-2</italic>, each may have its unique functions, making a complicated modulation of large gene networks. Although we identified that the primary transcript of <italic>MIR181B-2</italic> is more likely responsive to TNF-α stimulation in HUVECs and isolated primary mouse lung ECs using the systemic and endothelial-specific deficient <italic>Mir181a2b2</italic> mice, a recent study found that systemic double knockout of <italic>Mir181a1b1</italic> and <italic>Mir181a2b2</italic> improved HFD-induced obesity and insulin resistance (<xref ref-type="bibr" rid="bib51">Virtue et al., 2019</xref>), raising the possibility that targeting <italic>Mir181a1b1</italic> may impact distinct pathways and functions than <italic>Mir181a2b2</italic>. Future studies will be required to further characterize more details of these individual loci and responsiveness to diverse stimuli. In addition, while we found that MTX rescues <italic>Mir181b</italic> expression in HFD-fed mice, future studies will be of interest to validate MTX effects under chow-fed diet conditions. We also found that <italic>SMAD2</italic> and <italic>SMAD3</italic> expression decreased in eWAT of MTX-treated iEC-KO mice compared to flox-Cre mice only in response to MTX treatment. Future studies will need to clarify the mechanisms underlying a possible positive feedback loop involving the MTX-SMAD-<italic>MIR181B</italic> signaling pathway. Finally, while tamoxifen has been reported to affect GTT at early time points of 1–3 weeks after injection (<xref ref-type="bibr" rid="bib3">Ceasrine et al., 2019</xref>), in the current study we performed GTT and ITT at 12 weeks after initial injection of the tamoxifen metabolite 4-hydroxytamoxifen, making the likelihood of impact from 4-OHT extremely low as reported (<xref ref-type="bibr" rid="bib28">Liu et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Payne et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Tian et al., 2013</xref>; <xref ref-type="bibr" rid="bib55">Zhang et al., 2016</xref>).</p><p>In summary, we have identified that endothelial <italic>Mir181a2b2</italic> serves as a key regulator of pro-inflammatory stimuli-mediated EC activation, HFD-induced insulin resistance, and WAT inflammation. We also found that the anti-inflammatory effect of MTX was dependent on miR-181a2b2 expression in ECs, and that there is a positive correlation between the dose of MTX and <italic>Mir181b</italic> expression in circulating plasma and ECs. MTX prevented cytokine-induced EC activation through a unique downstream adenosine-<italic>ADORA3</italic>-SMAD-<italic>MIR181B</italic> signaling cascade. Therefore, strategies targeting this pathway to increase the expression of <italic>Mir181b</italic> in ECs may provide a novel translational approach to limit vascular inflammation in a range of chronic disease states.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture and transfection</title><p>HUVECs were purchased from Lonza (cc-2159) and cultured in EC growth medium EGM-2 (cc-3162). HEK 239 T cells (CRL-3216, ATCC) were cultured in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin. Cells were passaged less than five times for all experiments. Cell types were authenticated as follows: HUVECs, morphology; HEK293T, cell size and efficiency in transfection reporter assays. All cell lines were tested mycoplasma-free. Primary lung ECs from mice were isolated and cultured in as described (<xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). Briefly, isolated lungs from miR-181a2b2<sup>flox/flox</sup> and miR-181a2b2<sup>-/-</sup> mice were grinded with scissors (1 × 2 mm<sup>2</sup>) and digested with collagenase type II (Worthington) and dispase (Roche) (1 mg/ml each in DMEM/F12). Digestion was neutralized with DMEM/F12 medium containing 10% FBS, followed by centrifugation at 500 g for 10 min at 4°C and re-suspend in incubation buffer (PBS pH 7.2, 0.1% BSA, 2 mM EDTA, 0.5% FBS). ECs were captured using 10 µl anti-PECAM-1 (1:12.5, 557355, BD Pharmingen) antibody-conjugated sheep anti-rat IgG Dynabeads (00412289, Invitrogen) mixed with buffer containing the re-suspended cell pellet and incubated for 20 min at 4°C. After incubation, Dynabeads were mounted using the Magnetic Separation Rack and washed five times using wash buffer (PBS pH 7.2, 0.1% BSA) and cultured in gelatin (0.1%) pre-coated plates in EC medium (M1168, Cell Biologics) with kit (M1168-kit, Cell Biologics). EC identity was verified by both morphology and expression for CD31 by flow cytometry. HUVECs or primary lung ECs were plated on 12-well plates at 60,000/well or 150,000/well and allowed to grow to 80–90% confluency under growing conditions or 70–80% for transfection. Cells were pretreated with MTX (0.1, 1, 10 or 100 µM, M8407, Sigma), adenosine (1, 5, 10, 50 or 100 µM, A4036, Sigma), atorvastatin (1 µM, 1044516, Sigma), mevastatin (1 µM, M2537, Sigma), simvastatin (1 µM, S6169, Sigma), or rosuvastatin (1 µM, SML1264, Sigma) for 3 hr and stimulated with or without 10 ng/ml of recombinant human TNF-α (210-TA/CF, R and D Systems) or 20 ng/ml recombinant mouse TNF-α (410-MT/CF, R and D Systems) for various times, according to the experiment: Western blot, 8 hr; real-time qPCR, 1, 4, 7, or 12 hr. Lipofectamine 2000 transfection reagent (11668019, Invitrogen) was used for transfection, following the manufacturer’s instructions. On-Target plus human control siRNA-Smart poll, On-Target plus human AdoRA1 siRNA-Smart poll (L-005415–00, Dharmacon), On-Target plus human AdoRA2A siRNA-Smart poll (L-005416–00, Dharmacon), On-Target plus human AdoRA2B siRNA-Smart poll (L-005417–00, Dharmacon) or On-Target plus human <italic>ADORA3</italic> siRNA-Smart poll (L-005418–00, Dharmacon) were transfected at 100 nM. SiRNA control (AM4636) and validated siRNA including <italic>SMAD2</italic> (VHS41106), <italic>SMAD3</italic> (VHS41111), <italic>SMAD4</italic> (s8403) from Invitrogen were transfected at 20 nM. For co-transfection studies, On-Target plus human control siRNA-smart poll (100 nM), On-Target plus human <italic>ADORA3</italic> siRNA-smart poll (100 nM), miRNA negative control (10 nM, AM17110, Ambion), or pre-Mir181b (10 nM, PM12442, Ambion) were transfected as indicated in respective experiments. HUVECs were treated with 10 ng/ml recombinant human TNF-α 36 hr post-transfection at indicated times points.</p></sec><sec id="s4-2"><title>Luciferase activity assay and cell culture transfection</title><p>HEK 293 T cells were plated on 12-well plates at 300,000/well up to 70–80% confluency and transfected with 500 ng of the indicated <italic>Mir181a2b2</italic> promoter reporter constructs (Supplementary file 1) and 10 ng Renilla plasmid (E2231, Promega). Adenosine receptor siRNAs and SMAD2/3/4 siRNAs were co-transfected at 100 or 20 nM final concentration and cells were treated with MTX (10 µM) or Adenosine (50 µM) 24 hr post-transfection for 12 hr. Transfected cells were collected in 200 µl reporter lysis buffer (E1910, Promega) and luciferase activity was measured using a Dual-Luciferase reporter assay system (E1910, Promega). Each reading of luciferase activity was normalized to the Renilla activity.</p></sec><sec id="s4-3"><title>mRNA stability assay</title><p>For mRNA stability assays, HUVECs were incubated with 10 µM MTX or 50 µM Ad with 10 µg/ml Actinomycin D (SBR00013, Sigma) to inhibit transcription. At the indicated time points after the addition of Actinomycin D, cells were harvested and total RNA was extracted. The expression levels of <italic>pri-Mir181b1</italic> and <italic>pri-Mir181b2</italic> at each time point were measured by real-time qPCR as described below and normalized to the according Hprt levels. The remaining mRNA was determined by comparison with the expression level of the relevant gene at the zero time point (designated 100%) when Actinomycin D was added.</p></sec><sec id="s4-4"><title>Animal studies</title><p><italic>Mir181a2b2</italic><sup>flox/flox</sup> and <italic>Mir181a2b2</italic><sup>—/—</sup> mice were used as previously described (<xref ref-type="bibr" rid="bib20">Henao-Mejia et al., 2013</xref>) Mice expressing tamoxifen-inducible endothelial-specific VE-cadherin (VECad-Cre-ER<sup>T2</sup>; also known as Cdh5(PAC)-CreER<sup>T2</sup>) was kindly provided by R. Adams (<xref ref-type="bibr" rid="bib52">Wang et al., 2010</xref>). C57BL/6 mice were purchased from Charles River Laboratories (#027). Inducible EC-specific <italic>Mir181a2b2-</italic>deficient mice (<italic>Mir181a2b2</italic> <sup>flox/flox</sup>; VECad-Cre-ER<sup>T2</sup>) was generated by crossbreeding <italic>Mir181a2b2</italic><sup>flox/flox</sup> mice and VECad-Cre-ER<sup>T2</sup> mice. For induction of Cre activity, four weeks old male <italic>Mir181a2b2</italic><sup>flox/flox</sup> mice carrying the VECad-Cre-ER<sup>T2</sup> transgene were treated with either 4-hydroxytamoxifen (H6278, Sigma) (10 mg/kg, i.p.) or the same volume of vehicle for 5 consecutive days to generate EC-specific <italic>Mir181a2b2</italic>-deficient mice (<italic>Mir181a2b2<sup>i</sup></italic><sup>ECKO</sup>) and flox-Cre control mice (<italic>Mir181a2b2</italic><sup>ECfl/fl</sup>). For measurement of <italic>Mir181b</italic> in plasma, 8 weeks male C57BL/6 mice were tail vein injected with MTX (0.25 mg/kg or 1 mg/kg) or adenosine (4 mg/kg) for 3 hr and blood was collected in EDTA-containing tubes. Plasma samples were generated by centrifugation at 3000 rpm for 10 min and stored at −80°C. Total RNA was isolated from plasma by using the Total RNA Purification Kit from Norgen Biotek Corporation as described in our previous studies (<xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib33">MICU Registry et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). Male mice were age-matched in all experiments and cage-matched littermates were used for experiments. Analyses of in vivo samples were performed by blinded observers. All mice were maintained under SPF conditions at an American Association for the Accreditation of Laboratory Animal Care-accredited animal facility at the Brigham and Women’s Hospital. All animal protocols were approved by the Institutional Animal Care and Use Committee at Harvard Medical School, Boston, MA and conducted in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals.</p></sec><sec id="s4-5"><title>Diet-induced obesity, MTX administration, and glucose and insulin tolerance testing</title><p><italic>Mir181a2b2</italic><sup>flox/flox</sup>, <italic>Mir181a2b2</italic><sup>—/—</sup>, <italic>Mir181a2b2</italic><sup>ECfl/fl</sup> and <italic>Mir181a2b2</italic><sup>iECKO</sup> mice were injected i.p. with either MTX (M8407, Sigma, 1 mg/kg/week) or the same volume of vehicle control and placed on a high-fat diet (HFD) for 12–15 weeks containing 60 kcal% fat (D12492, Research Diets). Insulin tolerance testing (ITT) and glucose tolerance testing (GTT) were performed after HFD treatment as described in our previous study (<xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). Briefly, for GTT, mice were fasted for 12 hr and then injected i.p. with D-glucose (G7201, Sigma, 1 g/kg). ITT was performed on mice after 6 hr fasting and injected i.p. with recombinant human regular insulin (0.75 U/kg). Blood glucose levels were measured before injection and at 15, 30, 60, 90, and 120 min after glucose or insulin injection using One Touch Ultra glucometer (LifeScan).</p></sec><sec id="s4-6"><title>Immunohistochemistry (IHC)</title><p>IHC was performed as described in our previous study (<xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). Briefly, tissues were fixed with neutral buffered 10% formalin solution (HT501128, Sigma), embedded in paraffin wax, cut into sections at 6 μm, and deparaffinized. Antigen retrieval was performed using Bond ER1 (AR9961, Leica) for 30 min. Sections were incubated with anti-Mac-2 (553322, BD Pharmingen) in 1:900 dilutions for 90 min at room temperature. Primary antibodies binding to tissue sections was visualized using Bond Polymer Refine Detection kit (DS9800, Leica), and counterstained with hematoxylin. Representative images were captured by a digital system, and the Mac-2-postive areas in each section were determined by detecting the staining intensity with computer-assisted image analysis software (Image-Pro Plus, Media Cybernetics) and data were presented as a ratio of positive area to tissue area. Data were analyzed in a blinded fashion by two independent observers.</p></sec><sec id="s4-7"><title>Intima RNA isolation from aorta tissue</title><p>Isolation of intima RNA from aorta was performed as described in our previous studies (<xref ref-type="bibr" rid="bib44">Sun et al., 2014a</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2016</xref>). In brief, aortas were carefully flushed with PBS, followed by intima peeling using TRIzol reagent (15596018, Invitrogen). TRIzol was flushed for 10 s −10 s pause - another 10 s flushed and collected in an Eppendorf tube (~300–400 µL total) and snap frozen in liquid nitrogen.</p></sec><sec id="s4-8"><title>RNA isolation and real-time qPCR</title><p>Tissues were homogenized using TissueLyser II (Qiagen) according to manufacturer’s instructions. For RNA isolation TRIzol reagent (Invitrogen) or RNeasy kit (Qiagen) was used based on manufacturers protocol. Subsequent RT-qPCR was performed using High-Capacity cDNA Reverse Transcription kit (4368813, Applied Biosystems). For SyberGreen-based assay GoTaq qPCR Master Mix (A6001, Promega) was used; and for TaqMan Universal Master Mix II, UNG (4440038, Life Technologies) was used. Expression of mRNAs and miRNA expression were normalized to Hprt, β-actin, or U6 (Aglient, AriaMx Real-Time PCR System). Specific primers including Mir181b-5p (#001098), U6 (#001973), human-primary-miR-181a1b1 (#Hs03302966_pri), human-primary-miR-181a2 (#Hs03302889_pri), human-primary-Mir181b1 (#Hs03302963_pri), for TaqMan system were purchased from Life Technologies. Changes in expression were calculated using deltadelta Ct method. Primer sequences are described in (Supplementary file 2).</p></sec><sec id="s4-9"><title>RNA-Seq analysis</title><p>TRIzol reagent was used for RNA isolation from eWAT tissues based on manufacturers’ protocol. RNA-Seq analysis was performed after ribodepletion and standard library construction using Illumina HiSeq2500 V4 2 × 100 PE (Genewiz, South Plainfield, NJ). All samples were processed using an RNA-seq pipeline implemented in the bcbio-nextgen project (<ext-link ext-link-type="uri" xlink:href="https://bcbio-nextgen.readthedocs.org/en/latest/">https://bcbio-nextgen.readthedocs.org/en/latest/</ext-link>). Raw reads were examined for quality issues using FastQC (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>) to ensure library generation and sequencing were suitable for further analysis. Trimmed reads were aligned to UCSC build mm10 of the Mouse genome, augmented with transcript information from Ensembl release 79 using STAR. Alignments were checked for evenness of coverage, rRNA content, genomic context of alignments (for example, alignments in known transcripts and introns), complexity, and other quality checks using a combination of FastQC, Qualimap. Counts of reads aligning to known genes were generated by featureCounts (<xref ref-type="bibr" rid="bib26">Liao et al., 2014</xref>). Differential expression at the gene level were called with DESeq2. The total gene hit counts and CPM values were calculated for each gene and for downstream differential expression analysis between specified groups was performed using DESeq2 and an adapted DESeq2 algorithm, which excludes overlapping reads. Genes with adjusted FDR &lt; 0.1 and log2 fold-change (1.5) were called as differentially expressed genes for each comparison. Mean quality score of all samples was 36.12 within a range of 22,000,000–31,000,000 reads per sample. All samples had at least &gt;70% of mapped fragments over total. MetaCore (v20.2) was used for gene set enrichment analysis. RNA-Seq data are available through the Gene Expression Omnibus (GSE164251).</p></sec><sec id="s4-10"><title>Western blot</title><p>Tissues were homogenized using TissueLyser II (Qiagen) according to manufacturer’ instructions. Proteins were isolated using RIPA buffer (Boston BioProdcuts, BP-115) with protease inhibitor and phosphatase inhibitors. Protein concentrations were determined using Pierce BCA assay (Thermo Scientific). Twenty μg protein were loaded per lane on a 4–20% Mini-PROTEAN TGX Gel (Bio-Rad, 456–1096). Separated proteins were transferred to PVDF membranes using the Transfer Turbo Blot system (Bio-Rad) and Trans-Blot Turbo RTA Transfer Kit (Bio-Rad, 170–4272). The membrane was blocked with 5% nonfat milk in TBST for 1 hr at room temperature. After blocking, the membrane was incubated overnight at 4°C with antibodies against <italic>ADORA1</italic> (1:500, ab82477, abcam), <italic>ADORA2A</italic> (1:750, ab3461, abcam), <italic>ADORA2B</italic> (1:750, ab40002, abcam), <italic>ADORA3</italic> (1:500, ab203298, abcam), <italic>VCAM-1</italic> (1:1000, ab134047, abcam), <italic>ICAM-1</italic> (1:3000, BBA3, R and D Systems), <italic>E-Selectin</italic> (1:1000, BBA16, R and D Systems), p-AKT (1:1000, 4060, Cell Signaling), T-AKT (1:1000, 2920, Cell Signaling), β-actin (1:4000, 4970, Cell Signaling). Quantification of protein bands were performed using a luminescent image analyzer (BioRad, Chemidoc).</p></sec><sec id="s4-11"><title>Statistics</title><p>Statistical analyses were performed using GraphPad Prism version 7.0 (GraphPad Software, Inc, CA). Unpaired two-tailed Student <italic>t</italic> test was used to determine statistical significance between two groups. Multiple groups were analyzed by using One-way ANOVA. All data are presented as mean ± SEM. Number of experiment repeats, biological replicates and p values are indicated in figure legends.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the National Institutes of Health (HL115141, HL134849, HL148207, HL148355, HL153356 to MWF) the Arthur K Watson Charitable Trust (to MWF), the Dr. Ralph and Marian Falk Medical Research Trust (to MWF), the Swiss National Science Foundation (P2BEP3_162063 to SH), American Heart Association (18POST34030395 to SH.; and 18SFRN33900144 and 20SFRN35200163 to MWF) and National Natural Science Foundation of China (81570334 and 81770358 to TY) and Xiangya Eminent Doctor Project (#013 TY). We thank Zhiyong Deng for histology technical assistance.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources</p></fn><fn fn-type="con" id="con10"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All mice were maintained under SPF conditions at an American Association for the Accreditation of Laboratory Animal Care-accredited animal facility at the Brigham and Women's Hospital (protocol #2016N000182). All animal protocols were approved by the Institutional Animal Care and Use Committee at Harvard Medical School, Boston, MA and conducted in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title><italic>MiR181a2b2</italic> promoter sequences.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-58064-supp1-v2.pdf"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Primer list.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-58064-supp2-v2.pdf"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-58064-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Source data files have been provided for Figures 1 and 2. RNA-Seq data has been made accessible.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arner</surname> <given-names>P</given-names></name><name><surname>Kulyté</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MicroRNA regulatory networks in human adipose tissue and obesity</article-title><source>Nature Reviews Endocrinology</source><volume>11</volume><fpage>276</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2015.25</pub-id><pub-id pub-id-type="pmid">25732520</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baghdadi</surname> <given-names>LR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: a systematic review and meta-analysis</article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0235637</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0235637</pub-id><pub-id pub-id-type="pmid">32628710</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceasrine</surname> <given-names>AM</given-names></name><name><surname>Ruiz-Otero</surname> <given-names>N</given-names></name><name><surname>Lin</surname> <given-names>EE</given-names></name><name><surname>Lumelsky</surname> <given-names>DN</given-names></name><name><surname>Boehm</surname> <given-names>ED</given-names></name><name><surname>Kuruvilla</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tamoxifen improves glucose tolerance in a delivery-, Sex-, and Strain-Dependent manner in mice</article-title><source>Endocrinology</source><volume>160</volume><fpage>782</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1210/en.2018-00985</pub-id><pub-id pub-id-type="pmid">30759201</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>ES</given-names></name><name><surname>Cronstein</surname> <given-names>BN</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanisms of action of methotrexate</article-title><source>Bulletin of the Hospital for Joint Disease</source><volume>71</volume><fpage>5</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24219035</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charles-Schoeman</surname> <given-names>C</given-names></name><name><surname>Yin Lee</surname> <given-names>Y</given-names></name><name><surname>Shahbazian</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Elashoff</surname> <given-names>D</given-names></name><name><surname>Curtis</surname> <given-names>JR</given-names></name><name><surname>Navarro-Millán</surname> <given-names>I</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Cofield</surname> <given-names>SS</given-names></name><name><surname>Moreland</surname> <given-names>LW</given-names></name><name><surname>Paulus</surname> <given-names>H</given-names></name><name><surname>O'Dell</surname> <given-names>J</given-names></name><name><surname>Bathon</surname> <given-names>J</given-names></name><name><surname>Louis Bridges</surname> <given-names>S</given-names></name><name><surname>Reddy</surname> <given-names>ST</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Improvement of High-Density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial</article-title><source>Arthritis &amp; Rheumatology</source><volume>69</volume><fpage>46</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1002/art.39833</pub-id><pub-id pub-id-type="pmid">27483410</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chawla</surname> <given-names>A</given-names></name><name><surname>Nguyen</surname> <given-names>KD</given-names></name><name><surname>Goh</surname> <given-names>YP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Macrophage-mediated inflammation in metabolic disease</article-title><source>Nature Reviews Immunology</source><volume>11</volume><fpage>738</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1038/nri3071</pub-id><pub-id pub-id-type="pmid">21984069</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Qian</surname> <given-names>S</given-names></name><name><surname>Hoggatt</surname> <given-names>A</given-names></name><name><surname>Tang</surname> <given-names>H</given-names></name><name><surname>Hacker</surname> <given-names>TA</given-names></name><name><surname>Obukhov</surname> <given-names>AG</given-names></name><name><surname>Herring</surname> <given-names>PB</given-names></name><name><surname>Seye</surname> <given-names>CI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endothelial Cell-Specific deletion of P2Y2 receptor promotes plaque stability in Atherosclerosis-Susceptible ApoE-Null mice</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>37</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308561</pub-id><pub-id pub-id-type="pmid">27856454</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronstein</surname> <given-names>BN</given-names></name><name><surname>Naime</surname> <given-names>D</given-names></name><name><surname>Ostad</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>The antiinflammatory mechanism of methotrexate increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation</article-title><source>Journal of Clinical Investigation</source><volume>92</volume><fpage>2675</fpage><lpage>2682</lpage><pub-id pub-id-type="doi">10.1172/JCI116884</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronstein</surname> <given-names>BN</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Adenosine, an endogenous anti-inflammatory agent</article-title><source>Journal of Applied Physiology</source><volume>76</volume><fpage>5</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1152/jappl.1994.76.1.5</pub-id><pub-id pub-id-type="pmid">8175547</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronstein</surname> <given-names>BN</given-names></name><name><surname>Sitkovsky</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Adenosine and Adenosine receptors in the pathogenesis and treatment of rheumatic diseases</article-title><source>Nature Reviews Rheumatology</source><volume>13</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2016.178</pub-id><pub-id pub-id-type="pmid">27829671</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeOliveira</surname> <given-names>CC</given-names></name><name><surname>Acedo</surname> <given-names>SC</given-names></name><name><surname>Gotardo</surname> <given-names>EM</given-names></name><name><surname>Carvalho</surname> <given-names>PO</given-names></name><name><surname>Rocha</surname> <given-names>T</given-names></name><name><surname>Pedrazzoli</surname> <given-names>J</given-names></name><name><surname>Gambero</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Effects of methotrexate on inflammatory alterations induced by obesity: an in vivo and in vitro study</article-title><source>Molecular and Cellular Endocrinology</source><volume>361</volume><fpage>92</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2012.03.016</pub-id><pub-id pub-id-type="pmid">22480543</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deyab</surname> <given-names>G</given-names></name><name><surname>Hokstad</surname> <given-names>I</given-names></name><name><surname>Whist</surname> <given-names>JE</given-names></name><name><surname>Smastuen</surname> <given-names>MC</given-names></name><name><surname>Agewall</surname> <given-names>S</given-names></name><name><surname>Lyberg</surname> <given-names>T</given-names></name><name><surname>Ronda</surname> <given-names>N</given-names></name><name><surname>Mikkelsen</surname> <given-names>K</given-names></name><name><surname>Hjeltnes</surname> <given-names>G</given-names></name><name><surname>Hollan</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis</article-title><source>Arthritis Research &amp; Therapy</source><volume>19</volume><elocation-id>232</elocation-id><pub-id pub-id-type="doi">10.1186/s13075-017-1439-1</pub-id><pub-id pub-id-type="pmid">29041979</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamantis</surname> <given-names>E</given-names></name><name><surname>Kyriakos</surname> <given-names>G</given-names></name><name><surname>Quiles-Sanchez</surname> <given-names>LV</given-names></name><name><surname>Farmaki</surname> <given-names>P</given-names></name><name><surname>Troupis</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The Anti-Inflammatory effects of statins on coronary artery disease: an updated review of the literature</article-title><source>Current Cardiology Reviews</source><volume>13</volume><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.2174/1573403X13666170426104611</pub-id><pub-id pub-id-type="pmid">28462692</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gadangi</surname> <given-names>P</given-names></name><name><surname>Longaker</surname> <given-names>M</given-names></name><name><surname>Naime</surname> <given-names>D</given-names></name><name><surname>Levin</surname> <given-names>RI</given-names></name><name><surname>Recht</surname> <given-names>PA</given-names></name><name><surname>Montesinos</surname> <given-names>MC</given-names></name><name><surname>Buckley</surname> <given-names>MT</given-names></name><name><surname>Carlin</surname> <given-names>G</given-names></name><name><surname>Cronstein</surname> <given-names>BN</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The anti-inflammatory mechanism of sulfasalazine is related to Adenosine release at inflamed sites</article-title><source>Journal of Immunology</source><volume>156</volume><fpage>1937</fpage><lpage>1941</lpage><pub-id pub-id-type="pmid">8596047</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Schug</surname> <given-names>J</given-names></name><name><surname>McKenna</surname> <given-names>LB</given-names></name><name><surname>Le Lay</surname> <given-names>J</given-names></name><name><surname>Kaestner</surname> <given-names>KH</given-names></name><name><surname>Greenbaum</surname> <given-names>LE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tissue-specific regulation of mouse microRNA genes in endoderm-derived tissues</article-title><source>Nucleic Acids Research</source><volume>39</volume><fpage>454</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq782</pub-id><pub-id pub-id-type="pmid">20843784</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gareus</surname> <given-names>R</given-names></name><name><surname>Kotsaki</surname> <given-names>E</given-names></name><name><surname>Xanthoulea</surname> <given-names>S</given-names></name><name><surname>van der Made</surname> <given-names>I</given-names></name><name><surname>Gijbels</surname> <given-names>MJ</given-names></name><name><surname>Kardakaris</surname> <given-names>R</given-names></name><name><surname>Polykratis</surname> <given-names>A</given-names></name><name><surname>Kollias</surname> <given-names>G</given-names></name><name><surname>de Winther</surname> <given-names>MP</given-names></name><name><surname>Pasparakis</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis</article-title><source>Cell Metabolism</source><volume>8</volume><fpage>372</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2008.08.016</pub-id><pub-id pub-id-type="pmid">19046569</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>F</given-names></name><name><surname>Tang</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Lv</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Mu</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The interplay of LncRNA ANRIL and miR-181b on the inflammation-relevant coronary artery disease through mediating NF-κB signalling pathway</article-title><source>Journal of Cellular and Molecular Medicine</source><volume>22</volume><fpage>5062</fpage><lpage>5075</lpage><pub-id pub-id-type="doi">10.1111/jcmm.13790</pub-id><pub-id pub-id-type="pmid">30079603</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haskó</surname> <given-names>G</given-names></name><name><surname>Cronstein</surname> <given-names>BN</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Adenosine: an endogenous regulator of innate immunity</article-title><source>Trends in Immunology</source><volume>25</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.it.2003.11.003</pub-id><pub-id pub-id-type="pmid">14698282</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haskó</surname> <given-names>G</given-names></name><name><surname>Cronstein</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulation of inflammation by Adenosine</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>85</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00085</pub-id><pub-id pub-id-type="pmid">23580000</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henao-Mejia</surname> <given-names>J</given-names></name><name><surname>Williams</surname> <given-names>A</given-names></name><name><surname>Goff</surname> <given-names>LA</given-names></name><name><surname>Staron</surname> <given-names>M</given-names></name><name><surname>Licona-Limón</surname> <given-names>P</given-names></name><name><surname>Kaech</surname> <given-names>SM</given-names></name><name><surname>Nakayama</surname> <given-names>M</given-names></name><name><surname>Rinn</surname> <given-names>JL</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis</article-title><source>Immunity</source><volume>38</volume><fpage>984</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.021</pub-id><pub-id pub-id-type="pmid">23623381</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hjeltnes</surname> <given-names>G</given-names></name><name><surname>Hollan</surname> <given-names>I</given-names></name><name><surname>Førre</surname> <given-names>O</given-names></name><name><surname>Wiik</surname> <given-names>A</given-names></name><name><surname>Lyberg</surname> <given-names>T</given-names></name><name><surname>Mikkelsen</surname> <given-names>K</given-names></name><name><surname>Agewall</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-alpha-inhibitor</article-title><source>Clinical and Experimental Rheumatology</source><volume>31</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">23465067</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname> <given-names>KA</given-names></name><name><surname>Gao</surname> <given-names>ZG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Adenosine receptors as therapeutic targets</article-title><source>Nature Reviews Drug Discovery</source><volume>5</volume><fpage>247</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrd1983</pub-id><pub-id pub-id-type="pmid">16518376</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaeley</surname> <given-names>GS</given-names></name><name><surname>MacCarter</surname> <given-names>DK</given-names></name><name><surname>Pangan</surname> <given-names>AL</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Kalabic</surname> <given-names>J</given-names></name><name><surname>Ranganath</surname> <given-names>VK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Clinical responses and synovial vascularity in obese rheumatoid arthritis patients treated with adalimumab and methotrexate</article-title><source>The Journal of Rheumatology</source><volume>45</volume><fpage>1628</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.3899/jrheum.171232</pub-id><pub-id pub-id-type="pmid">30173153</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>F</given-names></name><name><surname>Galarraga</surname> <given-names>B</given-names></name><name><surname>Belch</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The role of endothelial function and its assessment in rheumatoid arthritis</article-title><source>Nature Reviews Rheumatology</source><volume>6</volume><fpage>253</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2010.44</pub-id><pub-id pub-id-type="pmid">20351705</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisiel</surname> <given-names>B</given-names></name><name><surname>Kruszewski</surname> <given-names>R</given-names></name><name><surname>Juszkiewicz</surname> <given-names>A</given-names></name><name><surname>Raczkiewicz</surname> <given-names>A</given-names></name><name><surname>Bachta</surname> <given-names>A</given-names></name><name><surname>Tłustochowicz</surname> <given-names>M</given-names></name><name><surname>Staniszewska-Varga</surname> <given-names>J</given-names></name><name><surname>Kłos</surname> <given-names>K</given-names></name><name><surname>Duda</surname> <given-names>K</given-names></name><name><surname>Bogusławska-Walecka</surname> <given-names>R</given-names></name><name><surname>Płoski</surname> <given-names>R</given-names></name><name><surname>Tłustochowicz</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Methotrexate, cyclosporine A, and biologics protect against atherosclerosis in rheumatoid arthritis</article-title><source>Journal of Immunology Research</source><volume>2015</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1155/2015/759610</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>He</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Franck</surname> <given-names>G</given-names></name><name><surname>Deng</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Haemmig</surname> <given-names>S</given-names></name><name><surname>Wara</surname> <given-names>AK</given-names></name><name><surname>Icli</surname> <given-names>B</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Feinberg</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MicroRNA-181b inhibits thrombin-mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10</article-title><source>The FASEB Journal</source><volume>30</volume><fpage>3216</fpage><lpage>3226</lpage><pub-id pub-id-type="doi">10.1096/fj.201500163R</pub-id><pub-id pub-id-type="pmid">27297585</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Hu</surname> <given-names>T</given-names></name><name><surname>He</surname> <given-names>L</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name><name><surname>Tian</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>He</surname> <given-names>L</given-names></name><name><surname>Pu</surname> <given-names>W</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>Fang</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>Y</given-names></name><name><surname>Duan</surname> <given-names>S</given-names></name><name><surname>Hu</surname> <given-names>C</given-names></name><name><surname>Hui</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Quertermous</surname> <given-names>T</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>Red-Horse</surname> <given-names>K</given-names></name><name><surname>Wythe</surname> <given-names>JD</given-names></name><name><surname>Zhou</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic targeting of sprouting angiogenesis using Apln-CreER</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6020</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7020</pub-id><pub-id pub-id-type="pmid">25597280</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loyer</surname> <given-names>X</given-names></name><name><surname>Potteaux</surname> <given-names>S</given-names></name><name><surname>Vion</surname> <given-names>AC</given-names></name><name><surname>Guérin</surname> <given-names>CL</given-names></name><name><surname>Boulkroun</surname> <given-names>S</given-names></name><name><surname>Rautou</surname> <given-names>PE</given-names></name><name><surname>Ramkhelawon</surname> <given-names>B</given-names></name><name><surname>Esposito</surname> <given-names>B</given-names></name><name><surname>Dalloz</surname> <given-names>M</given-names></name><name><surname>Paul</surname> <given-names>JL</given-names></name><name><surname>Julia</surname> <given-names>P</given-names></name><name><surname>Maccario</surname> <given-names>J</given-names></name><name><surname>Boulanger</surname> <given-names>CM</given-names></name><name><surname>Mallat</surname> <given-names>Z</given-names></name><name><surname>Tedgui</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice</article-title><source>Circulation Research</source><volume>114</volume><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302213</pub-id><pub-id pub-id-type="pmid">24255059</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>S</given-names></name><name><surname>Tian</surname> <given-names>XY</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Mu</surname> <given-names>C</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Bismuth</surname> <given-names>J</given-names></name><name><surname>Pownall</surname> <given-names>HJ</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Wong</surname> <given-names>WT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>22910</elocation-id><pub-id pub-id-type="doi">10.1038/srep22910</pub-id><pub-id pub-id-type="pmid">26956647</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangoni</surname> <given-names>AA</given-names></name><name><surname>Zinellu</surname> <given-names>A</given-names></name><name><surname>Sotgia</surname> <given-names>S</given-names></name><name><surname>Carru</surname> <given-names>C</given-names></name><name><surname>Piga</surname> <given-names>M</given-names></name><name><surname>Erre</surname> <given-names>GL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Protective effects of methotrexate against proatherosclerotic cytokines: a review of the evidence</article-title><source>Mediators of Inflammation</source><volume>2017</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1155/2017/9632846</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNelis</surname> <given-names>JC</given-names></name><name><surname>Olefsky</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Macrophages, immunity, and metabolic disease</article-title><source>Immunity</source><volume>41</volume><fpage>36</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.05.010</pub-id><pub-id pub-id-type="pmid">25035952</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>MICU Registry</collab><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Icli</surname> <given-names>B</given-names></name><name><surname>Wara</surname> <given-names>AK</given-names></name><name><surname>Belkin</surname> <given-names>N</given-names></name><name><surname>He</surname> <given-names>S</given-names></name><name><surname>Kobzik</surname> <given-names>L</given-names></name><name><surname>Hunninghake</surname> <given-names>GM</given-names></name><name><surname>Vera</surname> <given-names>MP</given-names></name><name><surname>Blackwell</surname> <given-names>TS</given-names></name><name><surname>Baron</surname> <given-names>RM</given-names></name><name><surname>Feinberg</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation</article-title><source>The Journal of Clinical Investigation</source><volume>122</volume><fpage>1973</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1172/JCI61495</pub-id><pub-id pub-id-type="pmid">22622040</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montesinos</surname> <given-names>MC</given-names></name><name><surname>Desai</surname> <given-names>A</given-names></name><name><surname>Delano</surname> <given-names>D</given-names></name><name><surname>Chen</surname> <given-names>JF</given-names></name><name><surname>Fink</surname> <given-names>JS</given-names></name><name><surname>Jacobson</surname> <given-names>MA</given-names></name><name><surname>Cronstein</surname> <given-names>BN</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68</article-title><source>Arthritis &amp; Rheumatism</source><volume>48</volume><fpage>240</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1002/art.10712</pub-id><pub-id pub-id-type="pmid">12528125</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname> <given-names>CE</given-names></name><name><surname>Hoelzinger</surname> <given-names>DB</given-names></name><name><surname>Truong</surname> <given-names>TN</given-names></name><name><surname>Chew</surname> <given-names>LA</given-names></name><name><surname>Myles</surname> <given-names>A</given-names></name><name><surname>Chaudhuri</surname> <given-names>L</given-names></name><name><surname>Egan</surname> <given-names>JB</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Gendler</surname> <given-names>SJ</given-names></name><name><surname>Cohen</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Chemotherapy can induce weight normalization of morbidly obese mice despite undiminished ingestion of high fat diet</article-title><source>Oncotarget</source><volume>8</volume><fpage>5426</fpage><lpage>5438</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14576</pub-id><pub-id pub-id-type="pmid">28076839</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nus</surname> <given-names>M</given-names></name><name><surname>Martínez-Poveda</surname> <given-names>B</given-names></name><name><surname>MacGrogan</surname> <given-names>D</given-names></name><name><surname>Chevre</surname> <given-names>R</given-names></name><name><surname>D'Amato</surname> <given-names>G</given-names></name><name><surname>Sbroggio</surname> <given-names>M</given-names></name><name><surname>Rodríguez</surname> <given-names>C</given-names></name><name><surname>Martínez-González</surname> <given-names>J</given-names></name><name><surname>Andrés</surname> <given-names>V</given-names></name><name><surname>Hidalgo</surname> <given-names>A</given-names></name><name><surname>de la Pompa</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endothelial Jag1-RBPJ signalling promotes inflammatory leucocyte recruitment and atherosclerosis</article-title><source>Cardiovascular Research</source><volume>112</volume><fpage>568</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw193</pub-id><pub-id pub-id-type="pmid">27496872</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payne</surname> <given-names>S</given-names></name><name><surname>De Val</surname> <given-names>S</given-names></name><name><surname>Neal</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Endothelial-Specific cre mouse models</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>38</volume><fpage>2550</fpage><lpage>2561</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.118.309669</pub-id><pub-id pub-id-type="pmid">30354251</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname> <given-names>RM</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Garcia-Cardena</surname> <given-names>G</given-names></name><name><surname>Luscinskas</surname> <given-names>FW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall</article-title><source>Circulation Research</source><volume>101</volume><fpage>234</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.151860b</pub-id><pub-id pub-id-type="pmid">17673684</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname> <given-names>PM</given-names></name><name><surname>Everett</surname> <given-names>BM</given-names></name><name><surname>Thuren</surname> <given-names>T</given-names></name><name><surname>MacFadyen</surname> <given-names>JG</given-names></name><name><surname>Chang</surname> <given-names>WH</given-names></name><name><surname>Ballantyne</surname> <given-names>C</given-names></name><name><surname>Fonseca</surname> <given-names>F</given-names></name><name><surname>Nicolau</surname> <given-names>J</given-names></name><name><surname>Koenig</surname> <given-names>W</given-names></name><name><surname>Anker</surname> <given-names>SD</given-names></name><name><surname>Kastelein</surname> <given-names>JJP</given-names></name><name><surname>Cornel</surname> <given-names>JH</given-names></name><name><surname>Pais</surname> <given-names>P</given-names></name><name><surname>Pella</surname> <given-names>D</given-names></name><name><surname>Genest</surname> <given-names>J</given-names></name><name><surname>Cifkova</surname> <given-names>R</given-names></name><name><surname>Lorenzatti</surname> <given-names>A</given-names></name><name><surname>Forster</surname> <given-names>T</given-names></name><name><surname>Kobalava</surname> <given-names>Z</given-names></name><name><surname>Vida-Simiti</surname> <given-names>L</given-names></name><name><surname>Flather</surname> <given-names>M</given-names></name><name><surname>Shimokawa</surname> <given-names>H</given-names></name><name><surname>Ogawa</surname> <given-names>H</given-names></name><name><surname>Dellborg</surname> <given-names>M</given-names></name><name><surname>Rossi</surname> <given-names>PRF</given-names></name><name><surname>Troquay</surname> <given-names>RPT</given-names></name><name><surname>Libby</surname> <given-names>P</given-names></name><name><surname>Glynn</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title><source>New England Journal of Medicine</source><volume>377</volume><fpage>1119</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname> <given-names>PM</given-names></name><name><surname>Everett</surname> <given-names>BM</given-names></name><name><surname>Pradhan</surname> <given-names>A</given-names></name><name><surname>MacFadyen</surname> <given-names>JG</given-names></name><name><surname>Solomon</surname> <given-names>DH</given-names></name><name><surname>Zaharris</surname> <given-names>E</given-names></name><name><surname>Mam</surname> <given-names>V</given-names></name><name><surname>Hasan</surname> <given-names>A</given-names></name><name><surname>Rosenberg</surname> <given-names>Y</given-names></name><name><surname>Iturriaga</surname> <given-names>E</given-names></name><name><surname>Gupta</surname> <given-names>M</given-names></name><name><surname>Tsigoulis</surname> <given-names>M</given-names></name><name><surname>Verma</surname> <given-names>S</given-names></name><name><surname>Clearfield</surname> <given-names>M</given-names></name><name><surname>Libby</surname> <given-names>P</given-names></name><name><surname>Goldhaber</surname> <given-names>SZ</given-names></name><name><surname>Seagle</surname> <given-names>R</given-names></name><name><surname>Ofori</surname> <given-names>C</given-names></name><name><surname>Saklayen</surname> <given-names>M</given-names></name><name><surname>Butman</surname> <given-names>S</given-names></name><name><surname>Singh</surname> <given-names>N</given-names></name><name><surname>Le May</surname> <given-names>M</given-names></name><name><surname>Bertrand</surname> <given-names>O</given-names></name><name><surname>Johnston</surname> <given-names>J</given-names></name><name><surname>Paynter</surname> <given-names>NP</given-names></name><name><surname>Glynn</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Low-Dose methotrexate for the prevention of atherosclerotic events</article-title><source>New England Journal of Medicine</source><volume>380</volume><fpage>752</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1809798</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sood</surname> <given-names>P</given-names></name><name><surname>Krek</surname> <given-names>A</given-names></name><name><surname>Zavolan</surname> <given-names>M</given-names></name><name><surname>Macino</surname> <given-names>G</given-names></name><name><surname>Rajewsky</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cell-type-specific signatures of microRNAs on target mRNA expression</article-title><source>PNAS</source><volume>103</volume><fpage>2746</fpage><lpage>2751</lpage><pub-id pub-id-type="doi">10.1073/pnas.0511045103</pub-id><pub-id pub-id-type="pmid">16477010</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speyer</surname> <given-names>CL</given-names></name><name><surname>Ward</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Role of endothelial chemokines and their receptors during inflammation</article-title><source>Journal of Investigative Surgery</source><volume>24</volume><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.3109/08941939.2010.521232</pub-id><pub-id pub-id-type="pmid">21275526</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Belkin</surname> <given-names>N</given-names></name><name><surname>Feinberg</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Endothelial microRNAs and atherosclerosis</article-title><source>Current Atherosclerosis Reports</source><volume>15</volume><elocation-id>372</elocation-id><pub-id pub-id-type="doi">10.1007/s11883-013-0372-2</pub-id><pub-id pub-id-type="pmid">24158362</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>He</surname> <given-names>S</given-names></name><name><surname>Wara</surname> <given-names>AKM</given-names></name><name><surname>Icli</surname> <given-names>B</given-names></name><name><surname>Shvartz</surname> <given-names>E</given-names></name><name><surname>Tesmenitsky</surname> <given-names>Y</given-names></name><name><surname>Belkin</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Blackwell</surname> <given-names>TS</given-names></name><name><surname>Sukhova</surname> <given-names>GK</given-names></name><name><surname>Croce</surname> <given-names>K</given-names></name><name><surname>Feinberg</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2014">2014a</year><article-title>Systemic delivery of microRNA-181b inhibits nuclear factor-κB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice</article-title><source>Circulation Research</source><volume>114</volume><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.302089</pub-id><pub-id pub-id-type="pmid">24084690</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Sit</surname> <given-names>A</given-names></name><name><surname>Feinberg</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>Role of miR-181 family in regulating vascular inflammation and immunity</article-title><source>Trends in Cardiovascular Medicine</source><volume>24</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2013.09.002</pub-id><pub-id pub-id-type="pmid">24183793</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Kang</surname> <given-names>S</given-names></name><name><surname>Belkin</surname> <given-names>N</given-names></name><name><surname>Wara</surname> <given-names>AK</given-names></name><name><surname>Icli</surname> <given-names>B</given-names></name><name><surname>Hamburg</surname> <given-names>NM</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Feinberg</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue</article-title><source>Circulation Research</source><volume>118</volume><fpage>810</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.308166</pub-id><pub-id pub-id-type="pmid">26830849</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomou</surname> <given-names>T</given-names></name><name><surname>Mori</surname> <given-names>MA</given-names></name><name><surname>Dreyfuss</surname> <given-names>JM</given-names></name><name><surname>Konishi</surname> <given-names>M</given-names></name><name><surname>Sakaguchi</surname> <given-names>M</given-names></name><name><surname>Wolfrum</surname> <given-names>C</given-names></name><name><surname>Rao</surname> <given-names>TN</given-names></name><name><surname>Winnay</surname> <given-names>JN</given-names></name><name><surname>Garcia-Martin</surname> <given-names>R</given-names></name><name><surname>Grinspoon</surname> <given-names>SK</given-names></name><name><surname>Gorden</surname> <given-names>P</given-names></name><name><surname>Kahn</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Adipose-derived circulating miRNAs regulate gene expression in other tissues</article-title><source>Nature</source><volume>542</volume><fpage>450</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1038/nature21365</pub-id><pub-id pub-id-type="pmid">28199304</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname> <given-names>CC</given-names></name><name><surname>Al-Rashed</surname> <given-names>F</given-names></name><name><surname>Calay</surname> <given-names>D</given-names></name><name><surname>Birdsey</surname> <given-names>GM</given-names></name><name><surname>Bauer</surname> <given-names>A</given-names></name><name><surname>Mylroie</surname> <given-names>H</given-names></name><name><surname>Morley</surname> <given-names>BJ</given-names></name><name><surname>Randi</surname> <given-names>AM</given-names></name><name><surname>Haskard</surname> <given-names>DO</given-names></name><name><surname>Boyle</surname> <given-names>JJ</given-names></name><name><surname>Mason</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation</article-title><source>Annals of the Rheumatic Diseases</source><volume>75</volume><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2014-206305</pub-id><pub-id pub-id-type="pmid">25575725</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>X</given-names></name><name><surname>Hu</surname> <given-names>T</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>He</surname> <given-names>L</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Yu</surname> <given-names>W</given-names></name><name><surname>He</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Zhong</surname> <given-names>TP</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Yan</surname> <given-names>Y</given-names></name><name><surname>Baldini</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>J</given-names></name><name><surname>Schwartz</surname> <given-names>RJ</given-names></name><name><surname>Evans</surname> <given-names>SM</given-names></name><name><surname>Gittenberger-de Groot</surname> <given-names>AC</given-names></name><name><surname>Red-Horse</surname> <given-names>K</given-names></name><name><surname>Zhou</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries</article-title><source>Cell Research</source><volume>23</volume><fpage>1075</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1038/cr.2013.83</pub-id><pub-id pub-id-type="pmid">23797856</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>H</given-names></name><name><surname>Cronstein</surname> <given-names>BN</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis</article-title><source>Bulletin of the NYU Hospital for Joint Diseases</source><volume>65</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">17922664</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virtue</surname> <given-names>AT</given-names></name><name><surname>McCright</surname> <given-names>SJ</given-names></name><name><surname>Wright</surname> <given-names>JM</given-names></name><name><surname>Jimenez</surname> <given-names>MT</given-names></name><name><surname>Mowel</surname> <given-names>WK</given-names></name><name><surname>Kotzin</surname> <given-names>JJ</given-names></name><name><surname>Joannas</surname> <given-names>L</given-names></name><name><surname>Basavappa</surname> <given-names>MG</given-names></name><name><surname>Spencer</surname> <given-names>SP</given-names></name><name><surname>Clark</surname> <given-names>ML</given-names></name><name><surname>Eisennagel</surname> <given-names>SH</given-names></name><name><surname>Williams</surname> <given-names>A</given-names></name><name><surname>Levy</surname> <given-names>M</given-names></name><name><surname>Manne</surname> <given-names>S</given-names></name><name><surname>Henrickson</surname> <given-names>SE</given-names></name><name><surname>Wherry</surname> <given-names>EJ</given-names></name><name><surname>Thaiss</surname> <given-names>CA</given-names></name><name><surname>Elinav</surname> <given-names>E</given-names></name><name><surname>Henao-Mejia</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The gut Microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs</article-title><source>Science Translational Medicine</source><volume>11</volume><elocation-id>eaav1892</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aav1892</pub-id><pub-id pub-id-type="pmid">31189717</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Nakayama</surname> <given-names>M</given-names></name><name><surname>Pitulescu</surname> <given-names>ME</given-names></name><name><surname>Schmidt</surname> <given-names>TS</given-names></name><name><surname>Bochenek</surname> <given-names>ML</given-names></name><name><surname>Sakakibara</surname> <given-names>A</given-names></name><name><surname>Adams</surname> <given-names>S</given-names></name><name><surname>Davy</surname> <given-names>A</given-names></name><name><surname>Deutsch</surname> <given-names>U</given-names></name><name><surname>Lüthi</surname> <given-names>U</given-names></name><name><surname>Barberis</surname> <given-names>A</given-names></name><name><surname>Benjamin</surname> <given-names>LE</given-names></name><name><surname>Mäkinen</surname> <given-names>T</given-names></name><name><surname>Nobes</surname> <given-names>CD</given-names></name><name><surname>Adams</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis</article-title><source>Nature</source><volume>465</volume><fpage>483</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/nature09002</pub-id><pub-id pub-id-type="pmid">20445537</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Yan</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>Q</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Zeng</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>An</surname> <given-names>X</given-names></name><name><surname>Toque</surname> <given-names>HA</given-names></name><name><surname>Dong</surname> <given-names>Z</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Fulton</surname> <given-names>DJ</given-names></name><name><surname>Weintraub</surname> <given-names>NL</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Bagi</surname> <given-names>Z</given-names></name><name><surname>Hong</surname> <given-names>M</given-names></name><name><surname>Boison</surname> <given-names>D</given-names></name><name><surname>Wu</surname> <given-names>C</given-names></name><name><surname>Huo</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulation of endothelial intracellular Adenosine via Adenosine kinase epigenetically modulates vascular inflammation</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>943</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-00986-7</pub-id><pub-id pub-id-type="pmid">29038540</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamasaki</surname> <given-names>E</given-names></name><name><surname>Soma</surname> <given-names>Y</given-names></name><name><surname>Kawa</surname> <given-names>Y</given-names></name><name><surname>Mizoguchi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells</article-title><source>British Journal of Dermatology</source><volume>149</volume><fpage>30</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.2003.05407.x</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Freichel</surname> <given-names>M</given-names></name><name><surname>van der Hoeven</surname> <given-names>F</given-names></name><name><surname>Nawroth</surname> <given-names>PP</given-names></name><name><surname>Katus</surname> <given-names>H</given-names></name><name><surname>Kälble</surname> <given-names>F</given-names></name><name><surname>Zitron</surname> <given-names>E</given-names></name><name><surname>Schwenger</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Novel endothelial Cell-Specific AQP1 knockout mice confirm the crucial role of endothelial AQP1 in ultrafiltration during peritoneal Dialysis</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0145513</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0145513</pub-id><pub-id pub-id-type="pmid">26760974</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>YS</given-names></name><name><surname>Nguyen</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>KC</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>Kuo</surname> <given-names>YC</given-names></name><name><surname>Chiu</surname> <given-names>JJ</given-names></name><name><surname>Shyy</surname> <given-names>JY</given-names></name><name><surname>Chien</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress</article-title><source>Circulation Research</source><volume>113</volume><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.280883</pub-id><pub-id pub-id-type="pmid">23603512</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58064.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Tontonoz</surname><given-names>Peter</given-names></name><role>Reviewing Editor</role><aff><institution>University of California, Los Angeles</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This paper outlines a microRNA-dependent mechanism for the anti-inflammatory actions the widely used drug methotrexate. The authors responded constructively to the majority of the concerns raised during review and the new data added has strengthened the conclusions.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Methotrexate attenuates vascular inflammation through an adenosine-microRNA dependent pathway&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Matthias Barton as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>Yang et al. describe a mechanism by which MTX treatment reverts insulin resistance and adipose inflammation. The authors report that the MTX metabolite adenosine, acting through Adenosine receptor 3, induces the expression of miR181b2, a microRNA previously shown by the same group to stabilize AKT and inhibit NF-κB signaling. The authors utilized endothelial cell-specific deletion of miR181a2/b2 to demonstrate that the effects of MTX on reducing adipose macrophage accumulation and insulin resistance rely on miRNA181b. Overall the finding are of interest but there are several concerns regarding methodology and experimental interpretation that would need to be addressed in a revised manuscript.</p><p>Essential revisions:</p><p>1) The magnitude of the induction of miR-181 by MTX or adenosine is small, with the majority of the changes in miR-181 ranging in less than a 1.5-fold increase in expression upon methotrexate treatment. While acknowledging that it is difficult to ascertain how many copies of a given miRNA are necessary to exert a functional effect, miR-181 is abundantly expressed in endothelial cells, therefore it is difficult to imagine that a less than 50% increase in expression would exert a meaningful change in functionality. This issue should be addressed and discussed.</p><p>2) Related to point 1, as the remainder of the manuscript suggests that miR181b is required for effects of MTX, is it possible that MTX-adenosine regulates the downstream function of miR181b (e.g. miRNA processing, regulate miRNP formation/miRNA binding protein abundance, etc..) instead of acting solely through transcriptional upregulation?</p><p>3) The concentrations of adenosine used in vitro in Figure 1 are very high compared to plasma levels of adenosine in humans. The authors use a dose range from 1-100uM, and in published work in humans the highest level measured was 2uM (see PMID:31379241). The authors see no effect of adenosine on miR-181 expression or other measurements at this concentration. It is difficult to conclude that adenosine is the mechanism by which MTX exerts its effects.</p><p>4) In order to conclude that the effects of MTX in ECs is mediated through miR-181, the authors need to do a more in-depth analysis of EC inflammation beyond VCAM1 expression. This is also important for the link in vivo in the high-fat diet feeding model in Figures 4 and 5. The characterization of EC inflammation via VCAM1 expression isn't sufficient to conclude that MTX alters insulin sensitivity via miR-181.</p><p>5) The mechanistic connection between SMAD3/4, miR-181 and the effects of methotrexate on insulin sensitivity need to be better defined. How do the authors believe that SMAD3/4 induction of miR-181 by MTX is occurring with respect to insulin sensitivity? While the promoter data presented in Figure 3 are convincing, it does not link well to the in vivo data presented in Figures 4-5.</p><p>6) The authors should explain why vehicle and 4-OHT injected experimental groups, instead of an experimental set up with cre-/cre+ and 4-OHT injection to both genotypes, were used in the experiments in Figure 5. The current scheme does not exclude the effect of 4-OHT on the readout. Tamoxifen has been reported to affect glucose metabolism (Ceasrine et al., 2019).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58064.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The magnitude of the induction of miR-181 by MTX or adenosine is small, with the majority of the changes in miR-181 ranging in less than a 1.5-fold increase in expression upon methotrexate treatment. While acknowledging that it is difficult to ascertain how many copies of a given miRNA are necessary to exert a functional effect, miR-181 is abundantly expressed in endothelial cells, therefore it is difficult to imagine that a less than 50% increase in expression would exert a meaningful change in functionality. This issue should be addressed and discussed.</p></disp-quote><p>We thank the reviewer for this point. We and others have demonstrated that moderate changes in miRNA expression (up or down) can have profound functional impact in the vascular endothelium in response to divergent acute and chronic inflammatory conditions (e.g. atherosclerosis, sepsis, thrombosis, and insulin resistance, among others) (Guo et al., 2018; Lin et al., 2016; Ma et al., 2016; Sun et al., 2014; Sun et al., 2012; Sun et al., 2016). We have incorporated this point in the Discussion section and revised in the text:</p><p>“MiRNAs are key post-transcriptional gene regulators and even moderate changes in miRNA expression can have profound functional impact in the vascular endothelium in response to divergent acute and chronic inflammatory conditions. […] Overexpression of miR-181b by tail vein injection of miR-181b mimics (~1.5-2.5-fold increase in miR-181b expression) improved acute vascular inflammation induced by endotoxemia (Sun et al., 2012), and chronic vascular inflammation triggered by atherosclerotic plaque formation (Sun et al., 2014), obesity and insulin resistance (Sun et al., 2016), and thrombin-induced arterial thrombosis (Lin et al., 2016).”</p><disp-quote content-type="editor-comment"><p>2) Related to point 1, as the remainder of the manuscript suggests that miR181b is required for effects of MTX, is it possible that MTX-adenosine regulates the downstream function of miR181b (e.g. miRNA processing, regulate miRNP formation/miRNA binding protein abundance, etc..) instead of acting solely through transcriptional upregulation?</p></disp-quote><p>While we find the MTX-adenosine impacts the pri-miR-181b and the promoter (transcriptionally), we cannot rule out the possibility that non-transcriptional mechanisms may be involved. We have incorporated this interesting point in the Discussion section. We have added new data in Figure 3—figure supplement 2 and incorporated this interesting point in the Discussion section and revised the text:</p><p>“At the post-transcriptional level, mRNA stability is an important factor determining mRNA abundance. […] These results indicate that the promoter region between -402 and -301 is likely required for MTX and Ad-induced transcriptional activity of the miR-181a2b2 gene and MTX and Ad may affect pri-miR-181b2 expression at both transcriptional and post-transcriptional levels.”</p><p>“Mechanistically, MTX activated an Ad-ADORA3-SMAD3/4 signaling cascade that transcriptionally activated miR-181a2b2 expression and modestly increased pri-miR-181b2 mRNA stability at the post-transcriptional level.”</p><disp-quote content-type="editor-comment"><p>3) The concentrations of adenosine used in vitro in Figure 1 are very high compared to plasma levels of adenosine in humans. The authors use a dose range from 1-100uM, and in published work in humans the highest level measured was 2uM (see PMID:31379241). The authors see no effect of adenosine on miR-181 expression or other measurements at this concentration. It is difficult to conclude that adenosine is the mechanism by which MTX exerts its effects.</p></disp-quote><p>We thank the reviewer for this point. It is generally thought that the concentrations of extracellular adenosine are below 1uM in unstressed tissues (PMID:11008982), whereas adenosine levels in inflamed or ischemic tissues can be as high as 100uM (PMID:14698282).</p><p>For example, plasma adenosine levels reached 4-10uM in patients with sepsis and in the 10-100uM range in the synovial fluid of patients with rheumatoid arthritis (PMID:11008982, 11248511). Moreover, similar results were found by a recent published work: 100uM adenosine significantly repress TNF-a-induced multiple adhesion molecules (VCAM-1, ICAM-1 and Eselectin) (PMID: 29038540). Consistent with these reports, we found that adenosine at 1uM, simulating “basal non-pathological” conditions did not affect miR-181b expression, whereas treatment with MTX or higher concentrations of adenosine (5-100uM) increased miR-181b expression (Figure 1B and E). We also find an increased trend in miR-181b expression with 5uM adenosine (Figure 1E). We have incorporated this point in the Discussion section and revised the text:</p><p>“Ad is continuously released by cells to the extracellular environment at a low concertation (less than 1 µM) in unstressed tissues, whereas Ad concentration can reach as high as 100 µM in inflamed or ischemic tissues (Hasko and Cronstein, 2004; Jacobson and Gao, 2006). […] Moreover, we demonstrated that the MTX and Ad-mediated protective effects on ECs were dependent on miR-181b expression.”</p><disp-quote content-type="editor-comment"><p>4) In order to conclude that the effects of MTX in ECs is mediated through miR-181, the authors need to do a more in-depth analysis of EC inflammation beyond VCAM1 expression. This is also important for the link in vivo in the high-fat diet feeding model in Figures 4 and 5. The characterization of EC inflammation via VCAM1 expression isn't sufficient to conclude that MTX alters insulin sensitivity via miR-181.</p></disp-quote><p>We thank the reviewer for this point. We have now performed new RNA-Seq studies: (1) in eWAT from the systemic miR-181a2b2 KO and flox control mice (i.e. under HFD) (Figure 4—figure supplement 2A-B); and (2) in eWAT from the systemic miR-181a2b2 KO and flox control mice in the presence of MTX (i.e. Under HFD+MTX) (Figure 4—figure supplement 2C-D) to obtain a more comprehensive portrait of the transcriptomic changes in response to high-fat diet and MTX. Consistent with our in vitro and in vivo findings for VCAM-1, Gene Set Enrichment Analyses (GSEA) of the mice under HFD conditions revealed the enrichment for several top pathways for cell adhesion (Figure 4—figure supplement 2A). Further exploration into the network analyses for these cell adhesion pathways demonstrated multiple adhesion molecules (VCAM-1, ICAM-1, PECAM-1, others) that were also regulated (Figure 4—figure supplement 2B). Interestingly, GSEA of the mice under HFD + MTX conditions revealed additional enrichment pathways related to cell cycle (Figure 4—figure supplement 2C-D). These more comprehensive analyses are now incorporated into the Results and Discussion sections:</p><p>“To better characterize the underlying mechanisms how MTX and miR-181a2b2 affects insulin resistance, we performed next-generation sequencing of RNA isolated from eWAT of these HFD-fed miR-181a2b2 flox and KO mice with or without MTX treatment. […] In eWAT from MTX-treated miR-181a2b2 flox and KO mice, GSEA found that cell cycle, inflammation, and chemotaxis pathways were more affected by MTX (Figure 4—figure supplement 2C-D).”</p><p>“Moreover, our data suggest that high-dose of MTX (1mg/kg) is essential to increase miR-181b expression and modulate a large gene network involving EC-leukocyte adhesion, chemotaxis, immune response, and cell cycle (Figure 4—figure supplement 2) in eWAT; consequently, this may ameliorate EC activation, insulin resistance, and adipose tissue inflammation. Several of these identified pathways (EC-leukocyte adhesion, chemotaxis, and immune response) are consistent with pathways known to be regulated by miR-181b (Guo et al., 2018; Lin et al., 2016; Ma et al., 2016; Sun, He, et al., 2014; Sun et al., 2012; Sun et al., 2016).”</p><disp-quote content-type="editor-comment"><p>5) The mechanistic connection between SMAD3/4, miR-181 and the effects of methotrexate on insulin sensitivity need to be better defined. How do the authors believe that SMAD3/4 induction of miR-181 by MTX is occurring with respect to insulin sensitivity? While the promoter data presented in Figure 3 are convincing, it does not link well to the in vivo data presented in Figures 4-5.</p></disp-quote><p>To better link our mechanistic studies in Figure 3 with the in vivo studies, we have performed additional studies that assessed the protein expression by Western of Smad2, Smad3, and Smad4 in eWAT from EC-miR-181a2b2 KO and flox control mice under HFD and HFD + MTX conditions. These data (Figure 5—figure supplement 3) demonstrate that Smad2 and Smad3 are markedly reduced in eWAT in the EC--miR-181a2b2 KO mice under HFD + MTX conditions compared to flox-cre controls, but not without MTX treatment. Given the role of miR-181b in mediating effects from MTX/Smad signaling, these findings suggest that there may be a positive feedback mechanism by which the loss of miR-181b attenuates Smad expression in response to MTX. We have incorporated these findings in the Results and Discussion sections:</p><p>“Because we identified that SMAD3/4 signaling contributed largely to miR-181b2 expression (Figure 3), we next investigated expression of SMADs in eWAT tissues from these HFD-fed flox-Cre and iEC-KO mice. We found that SMAD2 and SMAD3 expression decreased in MTX-treated iEC-KO mice compared to flox-Cre mice, whereas there were no differences between flox-Cre and iEC-KO mice without MTX treatment, suggesting a feedback mechanism involved in the MTX-SMAD-miR-181b cascade (Figure 5—figure supplement 3).”</p><p>“We also found that SMAD2 and SMAD3 expression decreased in eWAT of MTX-treated iECKO mice compared to flox-Cre mice only in response to MTX treatment. Future studies will need to clarify the mechanisms underlying a possible positive feedback loop involving the MTX-SMAD-miR-181b signaling pathway.”</p><disp-quote content-type="editor-comment"><p>6) The authors should explain why vehicle and 4-OHT injected experimental groups, instead of an experimental set up with cre-/cre+ and 4-OHT injection to both genotypes, were used in the experiments in Figure 5. The current scheme does not exclude the effect of 4-OHT on the readout. Tamoxifen has been reported to affect glucose metabolism (Ceasrine et al., 2019).</p></disp-quote><p>We thank the reviewer for this point. However, the study by Ceasrine et al., 2019, explored the role of tamoxifen on GTT after early time points of 1-3 weeks after injection. In addition, they found that oral tamoxifen delivery did not affect the GTT and resulted in lower plasma tamoxifen levels, but higher circulating levels of tamoxifen metabolites such as 4-hydroxytamoxifen (4-OHT), which is what we are using in this study. Furthermore, our GTT/ITT studies were performed almost 12 weeks after initial injection making the likelihood of impact from 4-OHT extremely low. Finally, numerous studies demonstrate similar experimental control as we did for 4-OHT (Payne, De Val and Neal, 2018; Zhang et al., 2016)(Liu et al., 2015; Tian et al., 2013). Nonetheless, we have incorporated this point as a potential limitation in the Discussion section and revised the text:</p><p>“Finally, while tamoxifen has been reported to affect GTT at early time points of 1-3 weeks after injection (Ceasrine et al., 2019), in the current study we performed GTT and ITT at 12 weeks after initial injection of the tamoxifen metabolite 4-hydroxytamoxifen, making the likelihood of impact from 4-OHT extremely low as reported (Payne, De Val and Neal, 2018; Zhang et al., 2016) (Liu et al., 2015; Tian et al., 2013).”</p></body></sub-article></article>